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Should Scientific Research in the Lead-up to Invention
Vitiate Obviousness under the Patented Medicines (Notice
of Compliance) Regulations: To Test or Not To Test? 
Ron A. Bouchard†
II. Introduction I. Abstract 
In Canada, the availability of generic drugs owes its
his article is an analysis of case law pertaining to pedigree to compulsory licensing. 1 As part of its per-T whether scientific research in the lead-up to inven- ceived obligations under the North American Free Trade
tion should vitiate a finding of obviousness in pharma- Agreement (NAFTA) and the World Trade Organiza-
ceutical litigation under the Patented Medicines (Notice tion’s Agreement on Trade Related aspects of Intellectual
of Compliance) Regulations (the ‘‘NOC Regulations’’). Property (TRIPS), Canada repealed its compulsory
The NOC Regulations belong to a class of legal instru- licensing regime for pharmaceuticals in favour of
ments referred to as ‘‘linkage regulations’’ that tie patent ‘‘ linkage regulations ’’ referred to as the Patented
protection for marketed pharmaceuticals to the Cana- Medicines (Notice of Compliance) NOC Regulations
dian drug approval process. Therefore, the NOC Regula- (the ‘‘NOC Regulations’’). 2 The substance and procedure
tions control entry of generic drugs into the market and of the NOC Regulations were modelled on analogous
access by the public to affordable medication. The issue legislation in the United States. 3 So-called linkage regula-
of testing arises out of the complex and inverse relation- tions tie patent protection for marketed pharmaceuticals
ship between inventiveness and obviousness in patent to the drug approval process, and thus control both entry
law such that the lower the threshold for inventive inge- of generic drugs into the Canadian market and access by
nuity in the patentability analysis, the higher the Canadians to affordable medication. Under the Cana-
threshold for parties attacking patents on grounds of dian linkage regulation regime, the typical route for a
obviousness. The present analysis demonstrates there is generic pharmaceutical company to obtain market
substantial uncertainty in Canadian jurisprudence over access for its product is to attack the relevant brand-
what constitutes the accepted test for obviousness. Some name pharmaceutical company’s patents for being either
cases stand for the proposition that no testing whatso- invalid (on the grounds of, for example, obviousness,
ever is allowed, others for the opposite proposition that anticipation, double patenting, and claims broader than
some testing is allowed, while still others purport to disclosure) or to claim that its product will not infringe
follow the former while actually applying the latter. His- listed patents. Given that a substantial percentage of the
torical cases supporting the ‘‘no testing’’ line of cases cases litigated under linkage regulations in Canada and
were analysed and found to offer no strong legal prece- the United States involve allegations of invalidity based
dent for this approach. It is suggested that courts adopt a on obviousness, 4 the test for obviousness determines, in
‘‘purposive test’’ for obviousness based on Canadian law part, the availability of generic medications in North
requiring patents to be construed purposively rather America.
than literally, federal policy underlying the NOC Regula-
tions requiring application of regulations in a manner When assessing the issue of obviousness, courts are
that is fair and balanced to all parties, and Supreme charged with addressing whether an invention is ren-
Court of Canada jurisprudence requiring fair, unequiv- dered obvious in light of previous disclosures. 5 This anal-
ocal, and predictable application of laws. The proposed ysis involves a determination of whether the impugned
test would be consistent with appellate court jurispru- invention represents an ‘‘inventive step’’ over previously
dence in other jurisdictions with analogous patent legis- disclosed inventions. 6 One problem that frequently
lation and policy. comes up in the obviousness analysis is whether or not
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experimental research or testing conducted by the pat- reasons. First, because courts are releasing inconsistent
entee in order to arrive at the invention constitutes this opinions on the issue (no testing versus some testing)
kind of inventive step. Under Canadian law, courts are and the opinions themselves are internally inconsistent
obliged to carry out the analysis from the perspective of a (courts say they are applying one standard but actually
person skilled in the relevant art casting their mind back apply another). Secondly, because judicial reasoning on
to the claim date. The specific question addressed in this the inventive capacity of persons skilled in the art contra-
paper is: Should scientific research and testing con- venes normative practices in the pharmaceutical
ducted during the lead-up to invention automatically industry, which in turn unfairly biases the legal test for
vitiate a finding of obviousness for a party attacking the obviousness in favour of patentees. Part IV contains rec-
patent on grounds of validity under the NOC Regula- ommendations for law reform. A purposive approach to
tions? obviousness is proposed which focuses not on binary
notions of testing/no testing, but rather on the essenceThe question is not an easy one. The concepts of
and context of inventive activity leading up to inventionobviousness and inventiveness in patent law are inversely
from the vantage point of the skilled technician. Therelated and linked through the inventive ingenuity of
decision of Justice Gibson in Bristol Myers Squibb v.relevant persons skilled in the art. A lower standard for
Novopharm8 is used as an example of how the centralinventiveness in the patentability analysis equates to a
elements of a purposive construction might be appliedhigher standard for obviousness for parties attacking the
to the test for obviousness. Finally, Part V discusses appli-patent on grounds of obviousness. Not surprisingly,
cation of the purposive approach to pharmaceutical liti-brand-name and generic pharmaceutical companies seek
gation conducted outside the umbrella of the NOC Reg-differing standards for inventiveness and obviousness.
ulations.Brand-name firms desire a relatively stringent standard
for inventiveness such that any research or testing under-
taken to arrive at an invention will result in a patent
monopoly. Under this strict standard, a generic company III. Statutory Requirement and
faces the fact that if evidence of testing is adduced then Classical Test 
its attack on patent validity must fail. By contrast, generic
y 1996 amendment to the Patent Act9 (the ‘‘Act’’), afirms seek a more flexible standard for inventiveness, B statutory requirement for obviousness came intowith the result that some testing is allowed without auto-
force for patent applications after October 1, 1989. 10 Sec-matically vitiating a finding of obviousness. As will be
tion 28.3 of the Act does not however provide a statutorydiscussed in detail below, it is perhaps not surprising that
definition of obviousness beyond reference to relevantcourts have had difficulty in grappling with this complex
persons skilled in the art. As noted by the courts11 andissue.
practitioners, 12 the common law test prior to codifica-The present analysis is split up into five parts. In Part tion has continued to be applied.I, the case law on obviousness is canvassed with the
The leading common law test for obviousness inobjective of determining whether or not there is in fact a
Canada was articulated by Justice Hugessen in Beloit v.coherent legal approach to the issue of scientific testing
Valmet:under the NOC Regulations. It is concluded that there is
The test for obviousness is not to ask what competentsubstantial uncertainty in Canadian jurisprudence over
inventors did or would have done to solve the problem.what constitutes the accepted test for obviousness under
Inventors are by definition inventive. The classical touch-the NOC Regulations. While many judges apply the stone for obviousness is the technician skilled in the art but
leading decision in Beloit v. Valmet7 to the effect that no having no scintilla of inventiveness or imagination; a par-
testing is allowed, others judges have seen fit to allow agon of deduction and dexterity, wholly devoid of intuition;
a triumph of the left hemisphere over the right. The ques-some testing provided it is non-inventive in nature, while
tion to be asked is whether this mythical creature (the manstill others have expressly adopted the reasoning in
in the Clapham omnibus of patent law) would, in the lightBeloit as the accepted test, yet applied the more flexible of the state of the art and of common general knowledge as
standard to the evidence at hand. Thus, courts are deliv- at the claimed date of invention, have come directly and
without difficulty to the solution taught by the patent. It is aering highly contradictory messages over what consti-
very difficult test to satisfy. . .tutes the degree of allowable testing under the obvi-
Every invention is obvious after it has been made, andousness rubric. Part II is an analysis of historical
to no one more so than an expert in the field. Where theprecedents cited in favour of the ‘‘no testing’’ approach. It
expert has been hired for the purpose of testifying, his infal-is concluded that there is no strong jurisprudential or lible hindsight is even more suspect. It is so easy, once the
scholarly grounds on which to base a finding of no teaching of a patent is known, to say, ‘‘I could have done
testing. Part III analyzes the implications of not having a that’’; before the assertion can be given any weight, one
must have a satisfactory answer to the question, ‘‘Why didn’tfair, equivocal, or predictable test for obviousness, and
you?’’ 13the effects of this on potential litigants. It is concluded
that the constitutional requirement for fairness, predict- Thus, for Justice Hugessen, and the considerable
ability, and certainty in law applies to the test for obvi- corpus of patent law relating to the obviousness test
ousness, and that this requirement is breached for two relying on his judgment, 14 there are only two perspec-
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tives from which to view a patent: that of an inventor, conducted in the laboratory or within the confines of a
and that of a person skilled in the art. One is completely library or presumably even on the Internet. This passage
inventive while the other is not inventive at all. The has a substantial history in the judicial analysis of obvi-
obviousness test is to be gauged only by the latter. As we ousness in Canada. 18 The second line of cases involve the
shall see below however, the lack of convergence notion that if more than a ‘‘mere scintilla’’ of inventive-
between the judicial construction of persons skilled in ness is exercised on the road to invention, 19 then the
the art and actual skilled technicians in the global phar- invention cannot be obvious. Both lines of cases are
maceutical industry has led to considerable judicial summarized in Table 1 infra. Applied together, they
manipulation of the case law in order to get around the result in a high barrier for parties alleging invalidity
restrictive language of Beloit. based on obviousness, leading Justice Hugessen in Beloit
to say ‘‘it is a very difficult test to satisfy’’. 20
The high watermark in pharmaceutical or chemicalIV. Analysis cases for the stringent standard is Justice Lederman’s trial
decision in Bayer v. Apotex, 21 In Bayer, the obviousness
Part I: NOC Case Law analysis focused on three interrelated issues: the ‘‘no
testing’’ approach to obviousness and the related ‘‘worth review of pharmaceutical case law demonstrates
a try’’ obviousness formulation, and whether a personA there is substantial confusion in Canadian courts
skilled in the art ‘‘would have’’ or ‘‘could have’’ arrived atregarding the amount of scientific research during the
the impugned invention. The case involved a compul-lead-up to invention allowed to be contemplated in the
sory license for nifedipine, a dihydropyridine Ca 2+obviousness analysis by persons skilled in the art. On one
channel blocker used in the treatment of various cardio-hand, many judges have articulated a stringent standard
vascular disorders. The issue of validity revolved aroundof ‘‘no experimentation or serious thought’’ (‘‘no testing’’
nifedipine’s poor activity as a solid dosage form, poorfor shorthand) while others have taken a more flexible
solubility in water as a liquid form, and significant lightapproach, allowing testing that is ‘‘due’’, ‘‘mechanical’’, or
sensitivity; all of which led to difficulties in arriving at a‘‘routine’’ without vitiating the obviousness attack.
dosage form with good bioavailability and rapid onset ofAdding to the confusion is the fact that still other courts
action.have articulated one standard while silently applying the
other. Thus it is hardly surprising that one recent deci- Apotex argued that the invention set out in Cana-
sion involved the application of a much less stringent dian Patent No. 981,582 (the ’582 patent) was obvious
test under anticipation than under obviousness, which is given the disclosure in a South African patent applica-
traditionally a much harder ground of attack to make tion that nifedipine could be used to treat acute angina
out in patent litigation. 15 Part I of the analysis is therefore when administered either intravenously or orally and
broken up into three sections: (a) decisions that apply the that it worked like nitrates, e.g., nitroglycerin.  Apotex
stringent standard, (b) decisions applying the more flex- contended it was obvious to put nifedipine in liquid
ible standard, and (c) decisions that claim to follow the form and then encase the solution in a soft gelatin cap-
former approach but apply the latter. sule in order to deliver it perlingually, as had been previ-
ously done for nitroglycerin.  Given the relevant prior art
(a) Stringent Standard and common knowledge attributed to persons skilled in
the art of pharmaceutical science, problems overcome byAs noted above, the test articulated in Beloit does
the ’582 patent, such as light sensitivity and insolubilitynot refer explicitly to scientific research or testing, in the
could easily be overcome through routine trial and errorlead-up to invention or otherwise. The origin of the
testing.  Apotex argued that such testing would be rou-stringent standard can be traced back to two lines of
tine workshop activity and therefore would involve nohistorical cases. 16 The first comprises legal commentary
inventive ingenuity. 22by Professor Harold Fox to the effect that no testing
whatsoever can be carried out in the context of the Apotex made out its case based on the ground that
obviousness analysis: testing conducted in the work-up phase to the invention
In order that a thing shall be ‘‘obvious’’ it must be by persons skilled in the art constituted non-inventive or
something that would directly occur to someone who was obvious testing. However, Justice Lederman rejected thissearching for some-thing novel, a new manufacture, or
approach, citing the Federal Court’s decision in Cabotwhatever it might be, without the necessity of his having to
Corp. v. 318062 Ont. 23  (citing Fox) to the effect that nodo any experimenting or serious thought, or research,
whether the research be in the laboratory or amongst litera- testing could be undertaken in the context of obvi-
ture. 17 ousness. This was true even under conditions where the
In this formulation, the standard for scientific impugned testing was both logical and reasonable in
research or testing that vitiates the obviousness attack is light of the prior art. 24 A second ground offered by Jus-
very stringent. Not only is no experimenting, serious tice Lederman was based on his interpretation of the
thought or research whatsoever allowed under the obvi- inventive capacity of relevant persons skilled in the art
ousness test, but this includes all research, whether it is articulated in Beloit. In particular he relied on the pro-
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position that persons skilled in the art are to be con- by the inventor crossed the line from mere workshop
strued as having ‘‘no scintilla’’ of inventiveness, imagina- activity into the realm of inventive ingenuity based on
tion, or intuition. 25 Such a person would, quite evidence before the court as interpreted by one skilled in
obviously, undertake no testing in order to arrive at an the appropriate art. 35 The approach taken in Bayer
invention. The notion that even a mere scintilla of inven- unduly benefits patentees because it minimizes the legal
tion is sufficient to justify patentability in the context of burden of having to adduce evidence proving that
a validity attack has a long history in Canada26 and the testing undertaken by them to arrive at the invention
United Kingdom.27 would have been inventive in nature. Rather, under the
Bayer test, it need only be proved that some testing wasRather than addressing the issue of testing conducted in the lead-up to the invention, followingdirectly, 28 Justice Lederman re-phrased Apotex’s argu- which a finding of obviousness is automatically vitiated.ment as ‘‘worth a try’’ rather than the routine experimen- Consequently, rejection of routine testing in favour oftation or workshop improvement approach advocated the no testing approach, substitution of the former withby Apotex. 29 As noted above, this formulation is a logical the worth a try approach, and reliance by the court onextension of the ‘‘no testing’’ approach; by definition the the distinction between could and would all marginalizeworth a try approach would allow some testing. Justice persons skilled in the art in the obviousness analysis.Lederman also expressed an abundance of caution
Table 1 (Appendix 1) below summarizes decisionsrelating to the issue of hindsight. 30 However, the worth a
to date where testing was not allowed in the obviousnesstry approach to obviousness differs significantly from
analysis. As in Tables 2-3 infra, the tabulated decisionsone addressing the issue of routine experimentation.
are split up into NOC and non-NOC cases. In Table 1,While it minimizes hindsight error it does so at the cost
the cases are further split into the two lines of casesof allowing a person skilled in the art to make an
underpinning the ‘‘no testing’’ approach: cases traceableinformed decision as to whether or not an invention is
back to Fox’s explicit injunction against testing, and casesobvious based on the evidence before the court as of the
traceable to the injunction against the exercise of moreclaim date. As such, it minimizes the role of persons
than a ‘‘mere scintilla’’ of inventiveness.skilled in the art in the obviousness determination,
which is then left in the hands of the presiding judge. As
discussed more fully below, this contradicts the require-
(b) Flexible Standard ments of section 28.3 of the Act, which stipulates that
Critical to understanding why and how a skilledpersons skilled in the art are to provide the lens through
formulator would (or could) contemplate testing a com-which the judiciary must gaze when addressing the issue
pound for its properties is the nature of the tacit andof obviousness.
focal codified knowledge36 possessed by the ordinary
A second important aspect of the decision in Bayer person skilled in the art in the pharmaceutical industry.
was the court’s distinction between whether a person As noted by Justice Snider in a recent case involving
skilled in the art ‘‘would have’’ or ‘‘could have’’ arrived at crystalline forms of azithromycin, pharmaceutical com-
the invention based on prior art. As with the worth a try panies litigating under the NOC Regulations are sophis-
approach, favouring the term ‘‘would’’ over ‘‘could’’ can ticated multinational firms, capable of rapidly and effi-
be seen as an extension of the no testing approach, as ciently conducting all necessary research relating to the
clearly one of these terms encompasses some testing optimal design, medical chemistry, formulation, dosage
while the other does not. The Federal Court of Appeal’s forms, manufacturing, and storage of pharmaceutical
‘‘cling free’’ case31 was cited as authority for the could products. 37 Indeed, once a pharmaceutical compound
versus would distinction. However, this distinction was has been synthesized, it routinely undergoes consider-
never made by Justice Urie in Beecham.32 Indeed, not able testing relating to each of these broad issues. 38 As
only was it not made, but it can be argued that Beecham pointed out by Wolfe and colleagues in the context of
is cited primarily in the case law for the proposition that innovation clusters, 39 the life sciences industry is heavily
to be obvious a person skilled in the art must come dependent on both synthetic and analytical knowledge
directly and without difficulty to the solution taught by bases. 40 Unfortunately, while the identity and inventive
the patent. The distinction by Justice Lederman between capacity of relevant persons skilled in the art have been
whether a person skilled in the art would versus could understood within the pharmaceutical industry for
have arrived at the invention has been applied in many many years, very few judges have made an attempt to
subsequent cases. 33 understand in detail the nature of the ‘‘persons’’, ‘‘skills’’,
or ‘‘art’’ in the context of cases under the NOC Regula-In rejecting any allowances for testing, the court in
tions. Indeed it can be argued that much of the confu-effect marginalized the skilled technician in the obvi-
sion in Canadian courts over the issue of testing can beousness analysis. As noted by Justice Martland writing in
traced back to a fundamental misreading of this issue. 41dissent in Farbwerke v. Halocarbon,34 use of the term
‘‘would’’ in this context amounts to a rejection of the Based on the above discussion, the relationship
more flexible Cripps Question, where emphasis is placed between inventiveness, obviousness and the inventive
on investigation into whether or not activity engaged in capacity of persons skilled in the art is crucial to a proper
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understanding of the issue at hand, as it informs the ‘‘routine’’, ‘‘workshop’’, or ‘‘mechanical’’ testing. An
normative context in which ‘‘routine’’ scientific research understanding of these terms is therefore central to a
occurs in the pharmaceutical sector. One of the few pragmatic test for obviousness that is faithful to the tacit
decisions in recent years where the issue was addressed and focal knowledge bases and normative practices
directly is Justice Reed’s decision in Apotex v. Hoffmann- within the global pharmaceutical industry. For example,
La Roche. 42 The case offers a good example of the fact in an early case involving a method for coating moulded
that a substantial amount of testing can be routinely masonry, the Exchequer Court of Canada held that obvi-
undertaken by a skilled formulator (or team of skilled ousness turns on the nature of the skills of the person
formulators) as part of the normal drug formulation skilled in the art as they are applied to the specific task at
exercise: hand. In particular, an invention is patentable only
where it is or not ‘‘beyond the expected skill of theOnce a compound such as trimethoprim has been syn-
thesized there are various tests through which it must go calling’’ or ‘‘beyond the skill of the routineer’’. 46 In other
before it becomes accepted as a new drug for treatment of words, testing within the skill of the routineer is neither
disease in humans. Research typically begins, as it did in this inventive nor supports the traditional patent bargain.case, with the synthesis of the new compound (or with the
The reasoning in Burns & Russell was relied on byisolation of that compound if the compound is one natu-
Justice Wetston in the Apotex v. Wellcome AZT trialrally occurring in nature). If this is done rationally the bio-
chemist will likely have some idea as to the potential decision:
properties of the compound. The compound once created is
There is no inventiveness in following an obvious andthen sent to a research facility for testing both in vitro (in
well-charted route using known techniques and processesglass) and in vivo (in life). In vitro testing is that which
involving known compositions unless the inventoroccurs in a test tube or more precisely in small glass saucer
encounters difficulties that could not have been reasonablyshaped dishes (petrie dishes). The effectiveness of the new
expected by a person versed in the art or overcome by thecompound against various types of bacteria is tested. If the
application of ordinary skill: Burns & Russell of Canada v.results are promising, in vivo tests are then conducted, often
Day and Campbell Ltd. (1965), 48 C.P.R. 207; Genentechusing mice because the behaviour of infectious diseases in
Inc.’s Patent, [1989] R.P.C. 147 (C.A.). 47mice parallels that in humans. Lastly the drug is tested in
humans, a stage referred to as clinical trials or clinical This reasoning has been followed in later cases
testing. under the NOC Regulations. For example, in
In any event, once trimethoprim had been successfully SmithKline Beecham v. Apotex,  the first of two ‘‘pink
synthesized by Drs. Hitchings and Roth it was sent in May hue’’ 48 cases, Justice Gibson, after citing Fox to the effectof 1956 to Dr. Bushby at the Wellcome Research Labora-
that a person skilled in the art should be ‘‘assumed to betory in Beckenham, Kent, England for in vitro and in vivo
testing . . . a man who is going to try to achieve success and not one
looking for difficulties or seeking failure’’, stated:Testing was not without difficulty. Initially the batches
of trimethoprim were of uneven purity. The most signifi- Having determined that a wet formulation of paroxe-
cant difficulty however arose from a report received in Sep- tine tablets gives rise to a ‘‘pink hue problem’’, a problem of
tember 1960 that chronic toxicity studies carried out in significant enough magnitude to cause a skilled person to
dogs had found severe leucopenia, that is a severe drop in seek out at least a partial solution to the problem, I am
the white blood cell count. But, those results could not be satisfied that a logical first step for a person skilled in the art
reproduced. By December 1961 clinical trials had com- would be to turn to the alternative formulation methods
menced at Hammersmith Hospital in London and Dr. disclosed by the ’060 Patent and to determine whether each
Bushby was attempting to interest other medical centres in or any of those alternative formulation methods would
doing likewise. 43 solve, or at least partially solve, the problem. Such an
enquiry would, I am satisfied, involve no inventive step orAs to whether such significant and ‘‘difficult’’ testing
skill. It would simply involve application of the inventionshould vitiate the obviousness attack, Justice Reed held
taught by the ’060 Patent. 49that evidence before the court indicated that testing of
Thus, routine investigation of the matter at handsulphamethoxazole with trimethoprim was nothing
includes logical, rational, or incremental steps towardother than an ‘‘entirely obvious routine, indeed, mechan-
solving the problem at issue. As exemplified by the rea-ical step to take’’. 44 Sensibly, the amount of allowable
soning of Justice Reed in the trimethoprim decision, thetesting is not without limitation. As noted by Justice
question to be answered is whether or not such steps areReed in a different decision, routine testing can only
inventive, e.g., nonobvious.render a claim invalid where it involves no inventive
step. 45 Central to the concept of allowable testing articu- Similarly, in Janssen-Ortho v. Novopharm,50 a case
lated by Justice Reed in both of these cases is that testing involving the l-isomer of the antibiotic levofloxacin, the
outside the bounds of obviousness involves an inventive court allowed non-inventive testing relating to a number
step, whereas that inside the obviousness fence does not. of characteristics of the compound at issue, including the
Although grounded in Supreme Court of Canada and (i) solubility, (ii) toxicity, and (iii) degree of antimicrobial
other appellate jurisprudence (cf. Table 2), this distinc- activity of levofloxacin compared to the previously dis-
tion has been largely ignored in cases where the more closed racemic mixture of the same drug ofloxacin. Jus-
stringent standard is applied. tice Mosley held that, given the previous patent on the
Many decisions under the NOC Regulations racemic mixture, it would have been obvious to a person
allowing some form of testing employ terms such as skilled in the art to conduct testing on the solubility,
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toxicity, and the degree of antimicrobial activity of the l- threshold for testing was ‘‘crystal clear and without the
isomer and that such testing was non-inventive. At need for experimenting or serious thought’’. 56 However,
various points in the judgment, the court described the court went on to find that no inventive ingenuity or
testing on these variables as mechanical, routine, ‘‘undue experimentation’’ was exercised in prescribing
involving simple analytical procedures that were uncom- sertraline for panic disorder or obsessive compulsive dis-
plicated and generally accepted, and that revealed no order:
new uses, surprising results, or properties. 51 Therefore, Those articles teach, prior to the effective date, that
even though the exact antimicrobial, solubility, and tox- current research suggested that SSRIs were logical candi-
icity characteristics of levofloxacin could not have been dates for use with OCD patients, that sertraline was in
clinical trials as a treatment for OCD, that the balance of thepredicted with absolute certainty without verification
evidence suggested SSRIs are effective in PD and prelimi-through testing, these characteristics would have been
nary results warrant investigating sertraline for PD. On thepredictable or obvious to persons skilled in the art and basis of this literature no inventive ingenuity, or undue
thus amenable to verification using routine analytical experimentation was required in order to prescribe ser-
tests available at the time of the claim date. traline for the treatment of PD or OCD. To paraphrase Mr.
Justice Wetston in Apotex Inc. v. Wellcome Foundation Ltd,Table 2 in Appendix 1 below summarizes decisions supra, there was no inventiveness in following an obvious
supporting some type of research or testing without and well-charted route using known techniques and known
automatically vitiating a finding of obviousness. compositions unless unexpected difficulties were encoun-
tered. 57Together, the decisions stand for the proposition that
acceptable testing is testing that falls short of inventive- A similar result was obtained in the second of two
ness and which allows the skilled technician to come cases involving the proton pump inhibitor omeprazole,
directly and without difficulty to the invention at issue. AB Hassle v. Genpharm.58 While Justice Layden-Ste-
These cases are clearly at odds with those summarized in venson stated clearly that for an invention to be obvious
Table 1. it must occur directly to the skilled person ‘‘without
serious thought, research or experiment’’, 59 the test she
(c) Cases That Cite Stringent Standard But Apply actually applied was that in the AZT trial decision to the
Flexible Standard effect that there is no inventiveness in following an
obvious and well-charted route using known techniquesConfusing the case law even further is a third line of
and processes involving known compositions unless thecases in which judges grappling with the complex evi-
inventor encounters difficulties that could not have beendence before them cite the stringent standard, yet, with
reasonably expected by a person versed in the art, orvarying degrees of silence, go on to apply the more flex-
overcome by the application of ordinary skill. Justiceible test. For example, in the Apotex v. Wellcome AZT
Layden-Stevenson found that nothing in Apotex’s evi-trial decision, Justice Wetston specifically cited Bayer to
dence indicated that testing conducted by Hassle wasthe effect that for an invention to be obvious, no
routine and, therefore, the invention was not obvious. 60thought, research or experiment could be undertaken on
Thus, while the court was willing to apply a more liberalthe road to discovery. 52 However, the standard actually
test than did Justice Campbell in the first omeprazoleapplied by the court was that of no ‘‘undue experimenta-
decision, 61 evidence adduced by Apotex was, as in thattion’’:
case, simply insufficient to demonstrate obviousness.There is no inventiveness in following an obvious and
well-charted route using known techniques and processes Another case on point is Novartis v. Apotex. 62involving known compositions unless the inventor
Novartis involved formulations of cyclosporin purportedencounters difficulties that could not be reasonably
expected by a person versed in the art or overcome by the to solve the problem of poor bioavailability through the
application of ordinary skill. 53 use of concentrated microemulsions. The ’150 patent
held by Novartis was invalid on grounds of anticipation,Consequently, the court accepted that some testing
obviousness, and because the claims were deemedcould be allowed in the obviousness analysis without
broader than the disclosure. The court dealt extensivelyvitiating a finding of obviousness. As noted earlier, Justice
with the issue of the skilled formulator and what wouldWetston’s reasoning on the issue parallels that of the
or would not be properly construed as part of theExchequer Court in Burns & Russell in this regard. 54
normal formulation exercise. Based on the facts beforeNevertheless, the court held that the proffered evidence
the court there were as many as four separate steps to gowas overly speculative and would have entailed undue
from the prior art to the invention. The main issue wasexperimentation in order to arrive at the impugned
phrased as follows:invention. 55 Even so, Justice Wetston clearly left open the
possibility that testing would not per se obviate a finding . . . Apotex alleges that the technician skilled in the art with
of obviousness. Thus, it is not surprising that many of the the teachings of the two ’667 and ’307 patents would under-
stand that to improve the stability and the bioavailabilitycases in Tables 2 and 3 refer to this decision.
produced by the delivery system of these patents, aSimilarly, in a case involving the selective serotonin microemulsion process would be needed so that a formula-
re-uptake inhibitor (SSRI) sertraline for panic and obses- tion of a high surface area of oil in contact with water which
sive-compulsive disorder, the court stipulated that the permits the cyclosporin to partition into the water and be
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absorbed across intestinal mucosa into the bloodstream, court, the court held that testing engaged in by Novartis
would result. was not inventive and therefore that the invention was
obvious. 66The key question is whether the formulator skilled in
the art would be aware that the smaller the droplets’ size,
A similar result was obtained in two decisionsthe higher the surface area of contact between oil and water
enhance, and thus, the better the drug blood levels that involving the  adrenoceptor antagonist carvedilol for
result. 63 congestive heart failure67 and the antibiotic azithro-
mycin. 68 In the latter decision, Justice Mosley stated that
Laying the groundwork for his analysis, Justice Blais no ‘‘experimentation or research’’ is permissible under
cited with approval the ‘‘worth a try’’ approach articu- the obviousness test. 69 However, later in his reasons he
lated in Bayer and Fox’s statement that to be obvious an actually found that the testing by Pfizer in order to prove
invention must be arrived at without any experimenting, that its dosage form of azithromycin did not demon-
serious thought or research. However, Justice Blais did strate a food effect was routine and did not constitute
not hold that testing engaged in by Novartis was per se undue experimentation. 70 Consequently, the invention
inventive. Rather, he addressed several complex and was obvious. Similarly, in Glaxosmithkline, Justice Noël
lengthy aspects of the evidence that shed important light cited Bayer and Fox to the effect that no research what-
on what a person skilled in the art would have known soever could be undertaken in the obviousness test, 71 but
and grappled with, presumably in the absence of inven- actually found that testing undertaken by GSK consti-
tive ingenuity. 64 The not-insignificant exercise the skilled tuted non-inventive testing, with the result that the
formulator faced in attempting to solve the problem invention was obvious. 72
before the court involved several overlapping considera-
tions, including that compositions of cyclosporin within A summary of cases where judges cite the stringent
the claimed patents would be in the form of a pre- standard as authority, but then go on to apply the more
concentrated microemulsion, that such emulsions flexible standard is provided in Table 3 in the Appendix
increase the rate of mass transfer of cyclosporin from the below. It is clear that a significant number of cases fall
oil to aqueous phase, that such an increase would be into this category.
inversely related to emulsion droplet size, and in turn
result in increased bioavailability of the drug in a
patient’s body:
(d) Summary 
Apotex suggests that in view of the teachings of the ’667
and ’307 patents and the literature available, a skilled formu- As can be seen from the data in Tables 1-3 andlator would understand that well formulated compositions
discussion thereof in the text, there are three divergentwithin the scope of the ’667 and ’307 patents would be a
microemulsion preconcentrate as claimed in claim 1 of the lines of case law pertaining to obviousness in Canada
’150 patent and it follows that emulsion and microemulsion under the NOC Regulations: (i) those that adopt a strin-
systems were developed as a means to increase the mass gent ‘‘no-testing’’ approach; (ii) those that adopt a flexible
transfer rates of the drug to the aqueous phase. It was also approach; and (iii) those that appear to adopt the formerwell known that the rates of the mass transfer of the drug to
approach but actually apply the latter. The cases under-the aqueous phase would increase as the size of the oil
droplets decreased, e.g., the smaller the droplets’ size, the pinning the no testing approach can themselves be split
higher the surface area of contact between oil and water into two groups. The first can be traced back to Professor
enhance, and thus, the better the drug blood levels. The real Fox’s legal commentary on this topic, while the secondquestion is whether every formulator skilled in the art
can be traced back to the intersection of obviousness andshould know that the higher [the] surface area of the dis-
inventiveness and the injunction against the exercise ofpersed phase (oil in water), that is a small particle size emul-
sion, the greater the absorption/bioavailability. even a mere scintilla of inventive ingenuity by persons
skilled in the art. The remainder of this article will con-
Apotex suggests that the emulsion and the microemul- centrate on the former line of cases; the second is dealtsion processes were commonly known in the industry and
with in forthcoming work. 73 Together, they are oftenthat the formulators skilled in the art were aware of these
referred to in NOC jurisprudence as the ‘‘acceptedprocesses at the time of the patent. 65
approach’’ to obviousness. This seems to conflict how-
From this passage it can be gleaned that based on ever with the data in Tables 2 and 3, which indicate the
known art regarding (a) microemulsion systems and (b) presence of two other distinct (and growing) contrary
the relationship between the size of emulsion droplets to lines of jurisprudence. The only conclusion one can
mass transfer rates, the skilled formulator would have draw from this analysis is that while Fox, Beloit and
known that: (i) reducing droplet size would increase Bayer are routinely cited as leading authority on the
droplet surface area, and (ii) that this increase in surface issue of testing there is no single authoritative line of
area would result in an increase in bioavailability due to jurisprudence indicating whether or not scientific testing
(iii) increased absorption, and that all of the above might in the lead-up period to an invention should vitiate a
(iv) solve known problems with cyclosporin bioavai- finding of obviousness. As such, there is considerable
lability. Based on this and other evidence before the confusion in Canadian courts on this issue.
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below, represents all of Justice Maclean’s analysis onPart II: Harold Fox Was Wise But Wrong
obviousness. As is clear from the passage, no review ofon the Issue of Testing 
law applicable to obviousness was undertaken:
That there is invention in the bleaching agent disclosed(a) Case Law 
by Haas, and his process or processes of producing the same,From Part I of the analysis it is clear that the strin- is not, I think, subject to any serious doubt, assuming for the
gent or strict approach to obviousness in Canada owes its moment that anticipation is not to be found in any of the
prior art cited, and this will be considered presently. I thinklegitimacy in large part to legal commentary by Harold
Haas undoubtedly made an important discovery, and as theFox. It is beyond question that Professor Fox was a
result of substantial and original research and experimentalleading figure of intellectual property law in Canada. His
work he has disclosed a process or processes, or means, fortextbooks are mainstays of patent analysis 74 and, as translating his discovery into practical and useful ends,
reflected in the case law described above, he continues to something that was not, I think, done before. The bleaching
of flour or dough, and the production of a white loaf ofbe heavily cited to this day. As a reminder, Professor
bread, was and is being successfully attained by the use ofFox’s precedent-setting passage on obviousness is as fol-
the bleaching agent prepared according to the process, andlows: by the means, described by Haas. This was, I think, some-
In order that a thing shall be ‘‘obvious’’ it must be thing novel and useful, particularly because of its adapta-
something that would directly occur to someone who was bility for use in bakeries as already mentioned, and I do not
searching for something novel, a new manufacture, or think there is any fair ground upon which it should be
whatever it might be, without the necessity of his having to denied the merit of a patentable invention, unless, as I have
do any experimenting or serious thought, or research, already stated, anticipation of it has been definitely estab-
whether the research be in the laboratory or amongst litera- lished. There would not seem to be any room for saying that
ture. 75 Haas was something obvious. In order that a thing shall be
‘‘obvious,’’ it must be something that would directly occurIt is obvious that for Fox, no research whatsoever
to someone who was searching for something novel, a newduring the lead-up period to an invention can be per- manufacture or whatever it might be, without the necessity
mitted in order to arrive at a conclusion of obviousness. of his having to do any experimenting or research, whether
the research be in the laboratory or amongst literature. HaasHowever, while it continues to be cited verbatim in both
discovered the existence of a flour bleaching enzyme in theNOC and non-NOC decisions, there are serious
soy-bean, he disclosed a process, and the sequence of theproblems with the issue of testing as dealt with by Pro- various steps in that process, by which a bleaching agent
fessor Fox. could best be made therefrom for commerce, and the prop-
erty that it will have when so made or manufactured, andTo begin with, the test for obviousness is not unlike
none of these things can, I think, be said to have beenthat for anticipation even though the legal requirements obvious. 81
for both otherwise differ significantly. 76 Indeed, obvi-
The statement by Justice Maclean to the effect ofousness and anticipation constitute separate and distinct
‘‘no experimenting or research’’ thus sits somewhatlegal requirements under Canadian, American, and
uncomfortably as a bald statement with no apparentBritish patent law. However, Fox’s position on anticipa-
precedent in Canadian law.tion parallels his injunction against experimenting in the
obviousness analysis: inventive ingenuity in an invention Neither of the two remaining decisions by Justice
exists where experiments were necessary to show Maclean82 entails a review of, or even mentions, previous
whether or not it could be usefully carried out. 77 In other case law pertaining to obviousness. Tellingly, these cases
words, experimentation trumps a finding of anticipation. are never cited in later decisions supporting the stringent
Consequently, the test for obviousness can be conflated standard: only the passage by Professor Fox is quoted,
into that for anticipation. As noted by Justice Hughes in minus any reference to the cases cited by him. Confusing
a recent NOC case involving levofloxacin, the lack of elements of Justice Maclean’s reasoning in Short Milling
inventiveness attributed to persons skilled in the art in have not escaped judicial notice, as revealed by the fol-
cases employing the stringent standard comes ‘‘perilously lowing passage from the decision of Justice Collier of the
close’’ to that for anticipation, with the result that obvi- Federal Court in Xerox v. IBM.:
ousness is ‘‘little different than a consideration of antici-
. . . Maclean, J., in J.R. Short Milling Company (Canada) Ltd.pation’’. 78 Ambiguity of this nature is likely responsible v. Geo Weston Bread and Cakes Ltd., et al., [1941] Ex.C.R.for the counter-intuitive (but not impossible) finding 69, at 86, used this test:
that a patent can be anticipated but not obvious over the
In order that a thing shall be ‘‘obvious’’, it must beprior art. 79 something that would directly occur to someone who
was searching for something novel, a new manufactureA second caveat regarding Fox’s obviousness analysis
or whatever it might be, without the necessity of hisis the narrow scope of case law cited in support of the
having to do any experimenting or research, whether thestringent standard. Indeed, three of the four cases cited research be in the laboratory or amongst literature.
by Fox were decided by a single judge, Justice Maclean of
I have some reservations about the phrase ‘‘whether thethe Exchequer Court, and there are questionable ele-
research be in the laboratory or amongst literature’’, havingments of Justice McLean’s analysis in these cases that in mind the putting in evidence, in proof of this defence, of
seem to have gone unnoticed. For example, paragraph 21 the so-called ‘‘prior art’’. Maclean, J’s expression ‘‘directly
of Short Milling v. Weston, 80 reproduced in its entirety occur’’ is, to my mind, a useful one. The form of question
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occasionally used at this trial was to this effect: Would an literature’’ vitiates an obviousness attack, just that some
ordinary skilled workman (at the relevant date) have been of either must have been involved in its opposite. Per-
led directly and without difficulty to . . . ? That inquiry, I haps this is the logical trap that Justice Maclean fell intothink, embraces the essence of the test formulated by
when providing his reasons in Short Milling.Maclean, J. 83
Fortunately, the judiciary in Canada have not fol- More important however is the fact that Justice
lowed Justice Maclean’s explicit disclaiming of Angers in fact allowed a substantial degree of testing in
researching the literature (also found in Fox84), as this the case before him in Sherwin-Williams. This case
would obviate persons skilled in the art having legiti- involved the validity of a patent held by General Electric
mate legal knowledge of the prior art, one of the pillars on new and improved alkyd resins and paints and
of the obviousness test even at the time of Short Milling. varnishes containing them. As shown by the evidence
The ‘‘directly and without difficulty’’ element of Justice before the court, there was significant prior art on such
Mclean’s test refers to the ‘‘Cripps Question’’ posed by Sir resins before General Electric conducted its own
Stafford Cripps in Sharp and Dohme v. Boots. 85 It is research testing on same:
submitted that Justice Collier was correct in highlighting
Around 1901 a chemist named Watson Smith triedthis section of Justice Maclean’s decision as the essence of
reacting glycerol and phthalic anhydride. His work isthe obviousness test as it was then known. It is further recorded in an article entitled ‘‘A new glycerol phthalate’’
submitted that Justice Maclean’s statement in Short which appeared in the Journal of the Society of Chemical
Milling, namely that that no experimenting or research Industries, of November, 1901. The article in question is
mentioned in Schedule I of the amended particulars ofcan be allowed under the Canadian obviousness test,
objection. It describes Watson Smith’s product as follows:should be overruled in favour of a more pragmatic and
evidence-based test. As characterized chiefly by its extraordinary insolu-
bility in almost all solvents. It is practically insoluble inIt is possible that the remaining case cited by Fox
alcohol ether and benzene also petroleum and petro-contains the seed of what may have led to the reasoning leum spirit. Its best solvent appears to be cold acetone
in Short Milling. In Canadian Industries v. Sherwin-Wil- but in this it is sparingly soluble. On pouring some of the
liams, 86 Justice Angers of the Exchequer Court quotes the solution on a watch glass and letting it evaporate sponta-
neously, the clear transparent resin deposited in minutefollowing passage by Justice Rinfret in Crosley Radio
drops, solidifying to hard transparent masses of the taste-Corp. v. Canadian General Electric87 regarding the role
less resinous body.of thought and experiment in the obviousness analysis:
Watson Smith had evidently discovered a new syntheticThe mere lack of obviousness is not sufficient to estab-
resin which however was wholly insoluble and unusable.lish invention. There must be inventive ingenuity: see
Yet it suggested all sorts of possibilities as an entirely newCrosley Radio Corporation and Canadian General Electric
synthetic product and, as time went on, the industry beganCompany Limited, where the Honourable Mr. Justice Rin-
to consider what might be done with this new synthesis.fret said (1936 SCR 551, at 555):
Around 1912 the Watson Smith resin was investigated by
Notwithstanding the very ingenious and exhaustive chemists in the employ of General Electric Company in the
argument of counsel for the appellant, we would hardly United States, their names being, among others, Callahan,
think, however, he would ask this Court to give a sacro- Arsem, Dawson, Howell and Friedburg. These chemists
sanct meaning to the use of the word ‘‘obvious’’ for the were trying to make out of this hard glassy substance of
purpose of discriminating between the category of Watson Smith, a sample whereof was filed as exhibit 24,
improvements which ought to be regarded as being something soluble in available solvents and thus industrially
properly inventions in the legal sense and the category of useful, something they could spread on a surface as a
those not so regarded. coating. 89
It has long been laid down in our courts that, in
The evidence adduced clearly demonstrates thatorder validly to support a patent, it was, of course, neces-
sary that the art, or the improvement thereon, should be General Electric was in the habit of conducting large-
new, that it must be useful and that it must not have scale routine research on a stable of compounds, and
been anticipated by prior knowledge or prior user by that it was deemed acceptable by the court at the timeothers within the meaning of sec. 7 of the Patent Act, in
Fox was writing his book not just for one person skilledforce at the time of the issuance of the patent in suit; but
that something additional was also required. It was essen- in the art, but rather an entire team of skilled chemists
tial that there should be invention and that one did not employed by this large sophisticated industrial company,
hold a valid subject-matter of a patent unless he showed to undertake significant experimental research, and thatthe exercise of the inventive faculties (See: Halsbury’s
such research should not vitiate the obviousness attack.Laws of England, vbis. Patents and Inventions, no. 288);
Notwithstanding the extensive amount of experimentaland that is to say, in the words of Lord Watson
(Thomson v. American Braided Wire Company (1889), 6 and theoretical research conducted by the General Elec-
R.P.C. 518 H.L.), ‘‘a degree of ingenuity . . . which must tric research group, Justice Angers found that the patent
have been the result of thought and experiment’’. 88 was obvious in light of the prior art. The result, and the
It is clear from the passage at the bottom of the means to get there, parallels that in the trimethoprim,
preceding paragraph that at no point in his decision did levofloxacin, cyclosporin and sertraline cases discussed
Justice Rinfret hold that ‘‘any experimenting or research, supra, where evidence of substantial testing was adduced
whether the research be in the laboratory or amongst without automatically vitiating a finding of obviousness.
10 Canadian Journal of Law and Technology
Finally, all four of the cases cited by Fox in support Part III: Requirement for an Unequivocal,
of his assertion that no testing can be contemplated in Predictable, and Fair Test 
the obviousness analysis were released between 1941
and 1945, yet the final edition (4th) of his textbook was
(a) Implications for the Issues of Certainty and Pre-published in 1969. Of note is the absence of several
dictability decisions released by the Exchequer Court of Canada
well before publication of the final edition. In particular, As noted above, the case law reviewed so far indi-
the omission of Burns & Russell 90 is notable, as it figures cates that there is no clear and consistent line of cases on
significantly in later decisions supporting a role for the issue of testing under the NOC Regulations. How-
testing (cf. Tables 2 and 3). Recall in that case that Justice ever, the Supreme Court of Canada has said that one of
Gibson found with reference to the existing case law that the primary functions of law is to give the public fair
routine testing is within the skill of persons skilled in the notice of the legal nature and consequences of its con-
art and thus does not support a patent monopoly.  This duct with reasonable certainty through the fair applica-
reasoning was adopted in the leading case of Apotex v. tion of laws by courts. 95As stated by Justice Gonthier in
Wellcome when the court held ‘‘there is no inventive- R. v. Nova Scotia Pharmaceutical Society, this notice
ness in following an obvious and well-charted route function is ‘‘broadly linked with the corpus of principles
using known techniques and processes involving known of government known as the ‘Rule of Law’, which lies at
compositions unless the inventor encounters difficulties the core of our political and constitutional tradition’’. 96
that could not have been reasonably expected by a The requirement for fairness, predictability, and cer-
person versed in the art or overcome by the application tainty in law applies in two important ways to the issue
of ordinary skill’’. 91 at hand. First, the case law review clearly illustrates that
Another early case noteworthy for having dealt there is a significant lack of certainty and predictability
directly with the issue of testing is the Supreme Court of with regard to the standard for testing within the obvi-
Canada decision in Lightning Fastener v. Colonial Fast- ousness rubric. This refers to the fact that courts are both
ener. 92 Justice Rinfret stated that inventions brought releasing inconsistent opinions on the issue (no testing
about through the exercise of mechanical skill do not versus some testing) and opinions which are themselves
involve an exercise of inventive ingenuity, and that it ‘‘is internally inconsistent (judges say they are applying one
not the object of the Patent Act to dignify by the name standard but actually apply another). Secondly, courts are
of invention every slight advance in the domain of adopting reasoning that flies in the face of normative
mechanism’’. A similar distinction was made by the practices within the pharmaceutical industry and
Exchequer Court in Pope Appliance v. Spanish River. 93 applying this reasoning in a manner that inherently and
Thus, while the need for caution in distinguishing thus unfairly biases the legal test for obviousness against
between inventive and non-inventive experimenting, second persons under the NOC Regulations.
thought, and research had been sounded by the courts, 94 In one of its leading patent cases, 97 the Supreme
there can be little question that by 1969 there was a well Court of Canada stipulated that the provisions of the Act
developed line of cases in Canada distinguishing the type and interpretation thereof by the judiciary should be fair
of routine or workshop testing advocated by Apotex in and predictable. Extending the principles enunciated in
Bayer, from inventive testing done on the road to a Nova Scotia Pharmaceutical, Justice Binnie noted that
patentable invention. there is a certain minimal standard of predictability that
must attach to patent law jurisprudence, beyond which
(b) Summary significant and improper economic harm can result to
The historical survey undertaken above casts doubt patent litigants. The court further held that it is within
on the legal foundations of the stringent standard for the bounds of proper patent policy to maintain this min-
obviousness. In the absence of strong supporting juris- imal level of certainty and predictability and to keep it
prudence, Professor Fox’s commentary in and of itself from slipping below that threshold:
stands as poor precedent for the proposition that any The scope of patent protection must not only be fair, it
scientific testing at all in the lead-up to invention should must be reasonably predictable.  A patent is, after all, a
public instrument issued under statutory authority whichvitiate a finding of obviousness. Together with the two
may result in severe financial consequences for its infringe-other lines of jurisprudence relating to this issue
ment. The scope of its prohibition should be made clear soreviewed in Part I and summarized in Tables 2 and 3 it is that members of the public may know where they can go
reasonable to conclude there is an absence of an une- with impunity. As was said in another public law connec-
tion by Gonthier J. in R. v. Nova Scotia Pharmaceuticalquivocal and predictable test for obviousness in Canada.
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Society, [1992] 2 S.C.R. 606, at p. 639, precision in public consumers.  Second, parties attacking a patent will lose
enactments is required to ‘‘sufficiently delineate an area of more cases under the NOC Regulations than would
risk’’ . . . otherwise occur with a fair and predictable test, which in
The patent owner, competitors, potential infringers and turn will broaden their risk zone. Third, the consequencethe public generally are thus entitled to clear and definite
to the public of not having a test for obviousness that isrules as to the extent of the monopoly conferred. This in
fair and predictable is that a significant percentage of theturn requires that the subjective or discretionary element of
claims interpretation (e.g., the elusive quest for ‘‘the spirit of population will be at risk of losing access to affordable
the invention’’) be kept to the minimum, consistent with medications. It is known, for example, that the longer a
giving ‘‘the inventor protection for that which he has actu- firm is able to maintain a dominant market position,ally in good faith invented’’ (Western Electric Co. v. Baldwin
particularly one relating to patented pharmaceuticals, theInternational Radio of Canada, [1934] S.C.R. 570, at p. 574).
longer it will continue to maintain monopolistic pricingPredictability is achieved by tying the patentee to its claims;
fairness is achieved by interpreting those claims in an schemes. 100 Finally, a high threshold test creates a lack of
informed and purposive way. 98 incentive for innovation in the pharmaceutical sector,
While the court was concerned with the scope of which in turn yields fewer and less innovative products
the claims at suit, the requirement for clear and definite for consumers and for potential inventors to build on.
rules can be legitimately extended from claim scope to Indeed, Varma and Abraham have described the obvi-
that of obviousness. Both analyses go to the heart of ousness test as the gate by which patent law minimizes
patent validity; one through the proper scope of the inefficient transfers of wealth under conditions where a
patent monopoly and the other through the existence of patentee obtains a right to exclude others from making
the monopoly itself. If a court finds that a given claim or or using their invention, yet does not add to the store of
set of claims are broader than the disclosure, then those public knowledge when a patent is granted on obvious
claims are deemed to be invalid. The same is true for subject matter. 101 The relevance of this to Canadian drug
obviousness, which can result in complete invalidation consumers is evident in the Supreme Court of Canada’s
of a patent rather than invalidation on a claim by claim recent statement that it ‘‘is entirely understandable’’ that
basis. brand-name pharmaceutical firms would avail them-
selves of provisions in the NOC Regulations allowingIt could also be argued that maintaining the
evergreening by ‘‘adding bells and whistles to a pio-threshold for allowable testing at the current stringent
neering product’’ after the original patent has expired. 102standard results in significant ‘‘chilling’’ of competition
The economic rationale for spending $10 million toto the benefit of patentees. This follows the resulting
make $500 million in profit instead of spending $500ambiguity and uncertainty faced by potential litigants. In
million to make $2 billion is relatively straightforward.Free World Trust, the Supreme Court of Canada held
The result of this situation is that brand-name drug com-that patent policy, not unlike competition law and
panies are strongly incented to leverage the regulationspolicy, should encourage and not discourage economic
to produce products that clearly do not benefit theactivity. In particular, the court noted that an improperly
public.expanded patent scope results in chilling of competition
to the detriment of both competitors and the public:
(b) Implications for the Issue of Fairness The patent system is designed to advance research and
development and to encourage broader economic activity. In addition to issues of certainty and predictability,
Achievement of these objectives is undermined however if the decisions of the Supreme Court of Canada in Novacompetitors fear to tread in the vicinity of the patent
Scotia Pharmaceutical and Free World Trust stand forbecause its scope lacks a reasonable measure of precision
the proposition that patent law should also be ‘‘fair’’ toand certainty.  A patent of uncertain scope becomes ‘‘a
public nuisance’’ (R.C.A. Photophone, Ld. v. Gaumont- all relevant parties. As noted by the court in the latter
British Picture Corp. (1936), 53 R.P.C. 167 (Eng. C.A.), at decision, fairness is achieved by interpreting patent law
p. 195). Potential competitors are deterred from working in in an informed and purposive way. Indeed, this repre-areas that are not in fact covered by the patent even though
sents a second overarching reason to revisit the test forcostly and protracted litigation (which in the case of patent
obviousness to ensure it is ‘‘fair, unequivocal and predict-disputes can be very costly and protracted indeed) might
confirm that what the competitors propose to do is entirely able’’: a test that inherently favours patentees would run
lawful. Potential investment is lost or otherwise directed. afoul of the fairness principal, particularly where the
Competition is ‘‘chilled’’.  The patent owner is getting more stated purpose and intent of the relevant enabling legisla-of a monopoly than the public bargained for. There is a high
tion is to balance the interests of all relevant parties andeconomic cost attached to uncertainty and it is the proper
policy of patent law to keep it to a minimum.99 ensure national public health interests are respected by
making affordable medication available. This concern isIn the pharmaceutical industry, the consequences of
particularly relevant in light of the fact that expendituresthis type of chilling are significant: First, as noted in Free
by Canadians on prescription drugs have risen by severalWorld Trust, patentees accrue more of a monopoly than
hundred per cent in the last two decades, 103 with nothat bargained for by the public. This skews the balance
slowing in the growth rate expected in the future.of patent law against potential competitors, concen-
trating wealth in the hands of fewer firms, and main- The purpose and intent of legislation can be
taining monopolistic pricing from the perspective of gleaned by government policy documents, including
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those referred to as Regulatory Impact Analysis State- language was used by Justice Binnie to the effect that
ments104 (‘‘RIAS’’). As noted by Justice Bastarache in that ‘‘[i]t seems clear that the NOC Regulations were
Bristol-Meyers Squibb v. Canada, it is appropriate for the introduced to help generic drug companies and at the
court to look to a RIAS for evidence of legislative intent same time curb potential patent abuse by them’’. 110
with respect to the NOC Regulations. 105 There have These statements are consistent with those made by Jus-
been several important RIAS documents relating to the tice Issac of the Federal Court of Appeal writing in dis-
NOC Regulations, most notably in 1993 when they sent in an earlier NOC decision. 111
came into force, in 1998 and 1999 following amend- Based on the above discussion, it is concluded that
ment to the NOC Regulations, and in December 2004 the purpose and intent of the NOC Regulations is to
and June 2006 with regard to data and market exclu- balance competing interests of brand-name and generic
sivity. On first pass, a reading of the 1993 RIAS suggests pharmaceutical companies in Canada. By balancing
the main issue at hand for legislators at the time the these interests the government has taken a well circum-
regulations came into force was shoring up the rights of scribed step to ensure the availability to the public of
patentees following the dismantling by the government access to affordable medication: as stated in the 2004
at the time of the compulsory licensing provisions. 106 For RIAS, ‘‘[t]he Government’s drug patent policy seeks to
example, the government stated: balance effective patent enforcement over new and inno-
As a general rule, judicial remedies are sufficient to vative drugs with the timely market entry of their lower
address patent infringement. However, with the enactment priced generic competitors’’. 112of Bill C-91 the government has created an exception to
patent infringement allowing generic competitors to under- In light of the balancing function of the NOC Reg-
take any activities necessary to work up a submission to ulations, the test for obviousness should be ‘‘fair’’ in that
obtain regulatory approval of a product. This removes a it should be neither unfairly biased nor inherentlypatent right that may have otherwise been available to pat-
skewed to the interests of one party. However, the cur-entees to prevent generic competitors from obtaining such
rent test effects just this result as it allows for no scientificregulatory approval of their products.
testing or research whatsoever without obviating aThese NOC Regulations are needed to ensure this new
finding of obviousness, and it does so independent of theexception to patent infringement is not abused by generic
drug applicants seeking to sell their product in Canada common practice in the art to undertake just such
during the term of their competitor’s patent while nonethe- testing as a matter of course. There is no recourse for
less allowing generic competitors to undertake the regula- generic firms when the ‘‘no testing’’ approach is applied:tory approval work necessary to ensure they are in a position
a patentee need only demonstrate some testing was per-to market their products immediately after the expiry of any
formed in the lead-up to the invention and the courtrelevant patents. 107
must find for brand-name firms. The person skilled inHowever, as can be gleaned from the second para-
the art, who under the provisions of section 28.3 of thegraph supra, in addition to safeguarding the interests of
Act, is to supply the lens through which the judiciary isbrand-name pharmaceutical firms, the government also
to gaze when assessing obviousness, is obliged by law tointended to protect the rights of generic firms under the
operate at the highest level of scientific and technicalnew regulations. The balancing function was been con-
sophistication, yet possess not even a scintilla of creativityfirmed more explicitly in the December 2004 RIAS:
or inventiveness when contemplating testing in the obvi-The proposed amendments are intended to restore the
ousness analysis. As discussed elsewhere, 113 this contra-balanced policy underlying the Patented Medicines (Notice
dicts scientific norms for persons skilled in the art. Asof Compliance) NOC Regulations (‘‘PM (NOC) NOC
Regulations’’) by reaffirming the rules for listing patents on such, the test is intrinsically and irrevocably skewed both
the register and clarifying when listed patents must be in theory and in practice to pharmaceutical patentees
addressed. and thus does not respect a policy of balance. For this
The Government’s drug patent policy seeks to balance reason, the test articulated in Beloit, Bayer, and progeny
effective patent enforcement over new and innovative drugs runs afoul of the constitutional requirement for fairnesswith the timely market entry of their lower priced generic
by contravening the stated purpose of the NOC Regula-competitors. The current manner in which that balance is
tions.realized was established in 1993, with the enactment of Bill
C-91, the Patent Act Amendment Act, 1992, S.C. 1993,
c. 2. 108
(c) Summary This balancing of interests was recently acknowl-
edged by the Supreme Court of Canada in its Biolyse In summary, a requirement for fairness, predict-
decision, in which Justice Bastarache stated that amend- ability, and certainty in application of the test for obvi-
ments to the NOC Regulations were intended to ‘‘con- ousness can be located in the Rule of Law, Supreme
firm the balance between providing effective enforce- Court patent jurisprudence and statements by legislators
ment of patent right, while ensuring that second and regarding the intent and purpose of the NOC Regula-
subsequent entry manufacturers’ drugs can enter the tions. This requirement is breached in two ways by the
market as soon as it is determined that they are not stringent test for obviousness. First, because it yields a
covered by a patent, or, where they are covered by a situation where there is a substantial lack of certainty
patent, immediately after the patent expiry’’. 109 Similar and predictability as to the correct standard for testing
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within the obviousness rubric. And second, because a particularly important consideration in jurisdictions
courts have adopted reasoning in the obviousness anal- such as Canada, where regulatory approval of
ysis that inherently and thus unfairly biases the legal test pharmaceuticals is controlled by linkage regulations,
against generic firms under the NOC Regulations. which in turn allows for line extension patents that can
be continually evergreened. 121
Part IV: Suggestion for an Unequivocal, In addition, the Supreme Court of Canada noted
Predictable, and Fair Test that courts must take a purposive approach not only to
infringement but also to validity, in order to avoid con-
struing claims differently for purposes of infringement(a) Purposive Construction of Obviousness 
and validity. 122 Similar reasoning applies to differences
As reviewed above, there is a small but growing between claim construction and obviousness. Finally, as
number of judges who have moved away from Beloit with claim construction, taking a purposive approach to
and Bayer to allow research or testing in NOC cases obviousness would satisfy the interpretive objective in
without obviating a finding of obviousness. Judicial rea- patent law of being ‘‘reasonable and fair to both the
soning in these cases typically entails articulation of patentee and the public’’. 123 As well, it would respect the
‘‘due’’, ‘‘rational’’, ‘‘incremental’’, ‘‘routine’’, ‘‘mechanical’’, public notice function of law.124
or ‘‘workshop’’ testing. In these decisions a finding for or
Particularly important to the issue at hand is that aagainst generic firms was based on the evidence before
purposive construction is said to achieve ‘‘flexibility andthe court, expert opinion, and an appreciation of contex-
fairness’’ in law by focusing on the essence or so-calledtual practices of persons skilled in the art in the pharma-
‘‘pith and marrow’’ of an invention. 125 This broad focusceutical industry. 114 As such, the tests applied by these
can be contrasted to the narrow focus on literal notionscourts was objective yet flexible.
of testing versus no testing in the stringent approach toA useful starting point for discussion of an unequiv-
obviousness (or the would versus could distinction). Aocal, predictable, and fair test is by way of analogy to the
purposive approach would involve an enquiry into theissue of claim construction, which according to the
nature of the research or testing leading up to the inven-Supreme Court of Canada must be made in a pragmatic
tion, the focal point being a determination of whether orand informed way. 115 In Whirlpool v. Camco, for
not the testing was inventive. The term ‘‘purposive’’ needexample, the court, following the Federal Court of
not be used; any term connoting a functional and prag-Appeal in Eli Lilly v. O’Hara116 and the House of Lords
matic approach aimed at assessing the essence of inven-in Catnic v. Hill & Smith, 117 held that patent claims
tive activity would suffice. No matter what the termi-should be construed ‘‘purposively’’, whereby emphasis is
nology used, the purposive approach comports well toplaced on locating the essence of an invention with the
the implicit reasoning employed by many of the judgesaid of persons skilled in the art (rather than interpreting
in decisions where testing was allowed, including thosethe words of the inventor literally). Viewing the patent
where the judiciary claimed to follow the stringent stan-through a skilled interpreter minimizes, in the words of
dard but actually applied the more flexible one.Lord Diplock, reliance on the type of literal and ‘‘meticu-
lous verbal analysis in which lawyers are too often A recent case under the NOC Regulations can be
tempted by their training to indulge’’. 118 used to illustrate how the central elements of a purposive
While the courts in Whirlpool and Catnic were construction might be applied to obviousness. BMS v.
concerned with claim construction rather than Novopharm126 involved gatifloxacin, a quinolonecarbox-
validity, 119 an emphasis on the ‘‘essential nature’’ of the ylic acid antibiotic. Evidence indicated that research into
invention and how it came to be is a constant feature in quinalones had been intense and extensive among
both analyses. In the case of claim construction it is highly qualified persons skilled in the art for 10 years
distinguishing between essential and non-essential ele- prior to the claim date. 127 Justice Gibson approved of
ments of the claim, whereas in the obviousness analysis it statements by Novopharm’s lead expert that the science
is the determination of whether the act of arriving at an involved in producing the invention (medicinal chem-
invention crosses the line between inventive and non- istry) was more predictable than experts for BMS had
inventive activity. Moreover, both assessments are to be claimed. 128 Regarding the issue of testing, the court
made contextually, 120 with the help of persons skilled in noted the prohibition in Beloit against any experiment,
the art. The issue of context is no less important to the thought, or research involving more than a ‘‘mere scin-
issue of obviousness, as no invention least of all those in tilla’’ of inventiveness. However, given the evidence
the multinational pharmaceutical industry arises in before him as to the inventive capacity of persons skilled
vacuo. All advances, be they large or small, evolve based in the art of pharmaceutical science, he rejected the test
on previous discoveries. To say that obviousness can only in Beloit in favour of the more flexible approach, casting
be found in the absence of experimentation, thought, or the definition of persons skilled in the art ‘‘well above
research is to deny the manner in which discoveries are the concept of an individual having no scintilla of inven-
made and reduced to practice, and essentially conflates tiveness or imagination’’. 129 Referring to the decisions in
the test for obviousness into that for anticipation. This is Apotex v. Wellcome130 (AZT), Pfizer v. Apotex131 (sert-
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raline) and Janssen-Ortho v. Novopharm132 (levoflox- in practice but that this need not be equivalent to legally
acin) discussed supra, he allowed routine testing that fell obvious, 137 even though this scenario runs against the
below the threshold of undue or inventive testing. This grain of analyzing a patented invention contextually138
included testing that produces surprising or unexpected through the eyes of a person skilled in the art, 139  with a
results. 133 As in Justice Reed’s articulation of allowable mind willing to understand140 all that is necessary in
testing in the Apotex v. Hoffmann LaRoche 134 order to successfully solve the problem before them141
trimethoprim case, the court noted that what constitutes enabled by all relevant prior art and best-practices in the
‘‘routine testing’’ in the context of obviousness must be industry at the time of the claim date. 142
dependant upon evidence adduced before the court. The Canadian approach can be contrasted with thatBased on such evidence Justice Gibson held that the in the United Kingdom not only with regard to obvi-patent was not obvious, finding specifically that the chief ousness but also anticipation, the latter of which is tradi-expert for Novopharm admitted on cross-examination tionally a harder ground of invalidity to make out. Forthat the starting point in his analysis was not the prior example, in the classic case of Van Der Lely v.art, but rather the invention in question. This led him to Bramford, 143 the House of Lords held that ordinaryconclude that Novopharm’s expert was engaged in a methods of trial and error testing can anticipate anclassic hindsight analysis. 135 invention, provided they do not involve an inventive
While the claims were ultimately held to be valid, step. Included in the scope of allowable testing are ordi-
Justice Gibson’s analysis is consistent with the purposive nary methods of trial and error that involve no inventive
approach outlined above. It was grounded in context at step and are generally necessary in applying any dis-
the time of the claim date and evidence adduced before covery to produce a practical result. 144 This contrasts
the court. His decision turned on evidence pertaining to sharply with the Canadian position on anticipation
the degree of activity in the field at the time of invention, articulated by Fox and applied in Beloit and later cases.
the somewhat predictable nature of the science and
The leading United Kingdom case on testing in thetechniques involved in producing the invention, the fact
context of obviousness is Lord Mustill’s Court of Appealthat some degree of testing is routinely employed in the
decision in Genentech. 145 The case stands for the pro-pharmaceutical industry, and the fact that persons skilled
position that an invention is obvious when analyzedin the art are in reality not completely devoid of inven-
contextually if it can be determined through well knowntive ingenuity. The latter two observations go to the
testing techniques involving trial and error. The courtheart of purposive construction as they are directed spe-
made a distinction between a notational skilled techni-cifically to whether research conducted by BMS was
cian attempting to put an invention into practice andinventive or not. The fact that evidence showed such
persons skilled in the art operating in a ‘‘discoverytesting was inventive does not detract from taking an
capacity’’ in a field where intelligence and problem-approach that seeks to understand the pith and marrow
solving abilities are both valued and normative. Theof the matter. Rather, it highlights the value of taking a
court found it appropriate in cases involving complexcontextual and evidence-based approach to obviousness
biomedical inventions to assume people who are skilledrather than focusing on binary notions of testing/no
in the art posses a substantial degree of problem-solvingtesting or would/could. The test is flexible rather than
ability. Indeed, the court held that ‘‘but for’’ the creativestringent, and thus is fair to both litigants.
skills of relevant persons skilled in the art they would notA purposive approach would also reconcile impor- have been included on the discovery team in the firsttant differences in obviousness jurisprudence in Canada place. It is these skilled technicians who make up theand the United Kingdom that persist in spite of the population of persons skilled in the art to which theincreasingly global nature of drug development and court must look when assessing obviousness. The rea-intellectual property rights attaching to pharmaceutical soning of Lord Mustill on this point parallels that ofinventions. As noted by Justice Lederman in Bayer,  a Justice Gibson in BMS v. Novopharm, Apotex v. Hoff-significant discrepancy exists in the inventive capacity of mann-LaRoche and the AZT trial decision, 146 and is pre-English and Canadian persons skilled in the art such that sent in varying degrees in all of the cases enumerated in‘‘making inquiries or testing, seems to be something Table 2 and many of those in Table 3. Another point ofoutside the ken of the notional Canadian skilled techni- convergence was the court’s holding that the skills of thecian’’. 136 Justice Lederman went on to say while it may person skilled in the art must be construed contextually,have been logical to a person skilled in the art to under- based on evidence brought before the court. 147take testing, that it was not open to the mythical skilled
technician who can not have an inquiring mind. Rather, Finally, Lord Mustill laid the burden for weighing
the law in Canada stands for the proposition that a considerations of obviousness squarely on the judiciary
skilled technician is expected to spontaneously exclaim notwithstanding the caution to avoid hindsight in the
‘‘I already know the answer and it is obvious’’. Reasoning obviousness analysis. 148 In looking to the essence of the
of this kind led Justice Blanchard in the recent Pfizer v. issue, courts in the United Kingdom are therefore
Novopharm azithromycin ‘‘food effects’’ case to say that charged with the burden of determining whether the
it can be scientifically obvious to arrive at an invention problem faced by the inventor ‘‘could have been over-
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come by pertinacity, sound technique, or trial and error, The primary ground of appeal in Teleflex is that the
with no more, or whether there would have been Federal Circuit has retreated significantly from the test
required a spark of imagination’’ beyond that properly laid down by the Supreme Court in its John Deere deci-
attributable to persons skilled in the art. It is left to the sion:
judge to form a mental picture of the art and skilled While the ultimate question of patent validity is one of
practitioner, and see how the latter measures up against law, the condition set forth in the Patent Act of 1952, 35
the problem which he or she is assumed to be U.S.C.S. §  103, which is but one of three conditions, each of
which must be satisfied, lends itself to several basic factualattempting to solve. Given the pragmatic and functional
inquiries: (1) the scope and content of the prior art are to beapproach taken by him it is not surprising that
determined; (2) differences between the prior art and thenumerous Canadian tribunals, including the Patent claims at issue are to be ascertained, and (3) the level of
Appeals Board, 149 the Federal Court of Canada, 150 and ordinary skill in the pertinent art resolved. Against this back-
ground, the obviousness or nonobviousness of the subjectthe Supreme Court of Canada, 151 have cited various por-
matter is determined. 156tions of Lord Mustill’s decision with approval, including
that on obviousness. 152 Consequently, determinations of patentability were
made on the basis of a comparison of the essential char-
acteristics of the alleged invention with those present in(b) Comparison with Calls for Law Reform in the
the relevant prior art. The court was clear that suchUnited States 
determinations were to be made in light of knowledge
There have been significant calls for reform in the possessed by relevant persons skilled in the art under the
law of obviousness in the United States. In particular, specific auspices of §103 of the 1952 Patent Act:
patent scholars have observed that the threshold for
A patent may not be obtained though the invention isobviousness has been increasingly construed by the Fed- not identically disclosed or described as set forth in section
eral Circuit as too onerous in light of the actual skills and 102 of this title (novelty), if the differences between the
knowledge of persons skilled in the relevant art, particu- subject matter sought to be patented and the prior art are
such that the subject matter as a whole would have beenlarly when compared with that in other research-heavy
obvious at the time the invention was made to a personsectors such as information technology. The law differs
having ordinary skill in the art to which said subject mattersignificantly from that in Canada, however, as courts in pertains. 157
the United States have tended to focus on differences
Thus, as in Canadian patent law, the lens throughbetween the structure and function of biomedical inven-
which the judiciary must gaze when determiningtions, 153 ignoring strong evidence of functional obvi-
whether the invention was a patentable advance over theousness in favour of analyzing the prior art in light of the
relevant prior art was that of the person having ordinarylevel of uncertainty relating to the structural aspect of
skill in the art, typically referred to in American legaltherapeutic molecules. Canadian courts, by contrast,
commentary as the PHOSITA. However, counsel fortend to take the evidence as they find it in cases under
KSR and numerous amicus curiae, including the Unitedthe NOC Regulations, focusing on structure or function
States Solicitor General and Twenty Four Intellectualas alleged by the attacking party in its Notice of Allega-
Law Professors (‘‘Law Professors’’), claim that the Federaltion.
Circuit has retreated from the John Deere factors,
The role of persons skilled in the art in the obvi- replacing them instead with a more stringent and inflex-
ousness analysis has recently garnered considerable ible test requiring that a specific ‘‘suggestion, teaching or
attention in the United States. In May 2006 the United motivation’’ to combine the relevant prior art teachings
States Supreme Court solicited the opinion of the Solic- in the manner claimed must be demonstrated to support
itor General on whether it should hear KSR Interna- a finding of obviousness. 158 This is analogous to Cana-tional Co. v. Teleflex Inc. et al., 154 a case involving a dian courts adopting the more stringent test in the con-
combination patent directed to an adjustable gas pedal text of testing. As noted by one prominent patent
for use in throttle control and an electronic control to scholar, 159 this has resulted in the gradual marginaliza-
communicate adjustments from the adjustable gas pedal tion of persons skilled in the art in obviousness cases
to the engine. KSR, a Canadian corporation, was granted generally, leaving room for considerable judicial review
summary judgment against Teleflex in its infringement of lower court findings of fact based on a less deferential
suit. The lower court decision was overturned on appeal standard of review.160
to the Federal Circuit, leading to the petition by KSR.
The case is highly pertinent to the present analysis as it The requirement to find in evidence such a specific
involves the first substantial determination of the nature piece of prior art contravenes the Supreme Court’s direc-
of a court’s proper reliance on persons skilled in the art tion in John Deere toward applying a ‘‘ functional
when deciding the issue of obviousness by the United approach’’ articulated by the court earlier in Hotchkiss v.
States Supreme Court since Graham v. John Deere. 155 Greenwood.161 As noted by Justice Clark in John Deere,
The court granted certiorari June 26, 2006 and heard the Hotchkiss formulation, ‘‘lies not in any label, but in
oral argument in late November 2006. A decision is its functional approach to questions of patentability’’. 162
expected in spring 2007. In practice, Hotchkiss has required a comparison
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between the subject matter of the patent, or patent appli- very difficult to satisfy’’. 170 It will be recalled that the
cation, and the background skill of the calling.  It has same concern was articulated by Justice Lederman in
been from this comparison that patentability was in each Bayer as grounds for the no testing/worth a try approach
case determined. As such, Hotchkiss and the pragmatic and the could /would distinction. As noted by the Solic-
approach advocated in Part IV(a) supra share a basic itor General in its Teleflex brief, however, the strict test
focus on the essence of an invention and the manner in articulated by the Federal Circuit constricts the test laid
which it came to be. Another point of convergence is down by the Supreme Court in John Deere, which calls
that the law is to be applied in a contextual manner on a for a flexible approach to obviousness. The Federal Cir-
case-by-case basis. As is true of obvious determinations in cuit’s test thus ‘‘fails to account for the problem-solving
Canada and the United Kingdom,163 the United States abilities of persons of ordinary skill in the art’’ and
Supreme Court was mindful of the burden on the judi- ‘‘underestimates the capabilities of courts and patent
ciary in rendering such determinations. However, as in examiners to ‘resist the temptation’ of hindsight and to
the United Kingdom (but not Canada) the court was consider fairly the question of obviousness’’. 171 As noted
clear that such difficulties were not unlike those encoun- by Justice Clark in John Deere, the ‘‘ultimate question’’
tered in any other type of case before the courts: of patent validity rests on the judgment, informed by
relevant facts on a case-by-case basis, of whether a personThis is not to say, however, that there will not be diffi-
of ordinary skill in the art would have found the inven-culties in applying the nonobviousness test. What is obvious
is not a question upon which there is likely to be uniformity tion as a whole obvious. 172 This echoes the more flexible
of thought in every given factual context. The difficulties, and purposive approach taken by Justice Gibson and
however, are comparable to those encountered daily by the Lord Mustill in their BMS v. Novopharm and Genentechcourts in such frames of reference as negligence and scienter,
decisions, respectively.and should be amenable to a case-by-case development.  We
believe that strict observance of the requirements laid down
here will result in that uniformity and definiteness which The test articulated by the Federal Circuit does fur-Congress called for in the 1952 Act. 164
ther violence to the scope of obviousness as it conflates it
Despite the clarity of the decisions in Hotchkiss and into that for anticipation. As noted by the Law Professors,
John Deere, it is claimed165 that the Federal Circuit has the obviousness requirement asks of the court to deter-
minimized the role of persons skilled in the art in the mine not what is already present in the prior art as of the
obviousness analysis through the assumption, 166 paral- claim date, but rather whether a person skilled in the art
leled in Canadian jurisprudence, that such persons are would deem the subject matter obvious in light of
incapable of innovation and inventiveness, and by whatever prior art exists as of the claim date. 173 In con-
viewing obviousness as a question of law rather than one trast, the Federal Circuit’s teaching-suggestion approach
of fact. 167 As in Canadian cases where the judiciary recite requires the prior art to contain a particularized sugges-
law standing for the proposition that no testing is tion, teaching, or motivation to ground a finding of obvi-
allowed but then find that the testing undertaken was in ousness: if no such specific suggestion, teaching, or moti-
fact non-inventive, the Federal Circuit’s jurisprudence on vation is put in evidence, then the invention must be
obviousness has apparently created a similar type of deemed nonobvious This is clearly contrary to the
double standard in the law by reciting the importance of United States Supreme Court’s ruling in John Deere,
persons skilled in the art to the obviousness analysis, leading the Solicitor General to recommend that KSR’s
then not depending on the skills or knowledge of such petition for writ of certiorari be granted. It is again remi-
persons when rendering decisions. 168 As claimed by the niscent of arguments made above in the context of Pro-
Solicitor General and the Law Professors in their respec- fessor Fox’s legal commentary that the stringent standard
tive briefs, this has resulted in a substantial lowering of for obviousness differs little from that for anticipation
the bar for patentability, with a concomitant diminution under current Canadian law with regard to testing.
in new discoveries and foreclosure of competitors’ use of
knowledge that would otherwise be in the public A final important issue arising out of Teleflex is the
domain. 169 This is reminiscent of the discussion by the distinction between inventive and non-inventive (or
Supreme Court of Canada in Free World Trust of the mechanical) testing. In its John Deere decision, the
effect of an improperly defined patent scope to create an United States Supreme Court made comments
undue ‘‘commercial risk zone’’ for competitors discussed regarding the role of persons skilled in the art relating tosupra. ‘‘routine testing’’ that are pertinent to the analysis of
The Federal Circuit has historically justified the rela- cases under the NOC Regulations. As noted supra, the
tively inflexible teaching-suggestion approach based on court looked to its previous decision in Hotchkiss to
the effort to avoid hindsight analysis, whereby persons interpret the proper scope of obviousness following its
skilled in the art use the hindsight of prior art disclosed codification in the United States Patent Act in 1952. In
after the priority date when analyzing the alleged inven- Hotchkiss, the court grappled with developing legal
tion at the time of the claim date. Hindsight is a difficult means of facilitating the public disclosure of inventions
problem to be sure, and was part of the reason for Justice that would not otherwise be disclosed or created but for
Hugessen’s claim in Beloit that the obviousness test ‘‘is the inducement of the patent monopoly. The court held:
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Unless more ingenuity and skill . . . were required . . . testing or would/could, but rather on the essence of
than were possessed by an ordinary mechanic acquainted inventive activity from the perspective of skilled persons
with the business, there was an absence of that degree of in the art casting their mind back to the claim date. Thatskill and ingenuity which constitute essential elements of
is, was the experimenting or research that led up to theevery invention. In other words, the improvement is the
work of the skilful mechanic, not that of the inventor. 174 invention inventive or not? An approach which focuses
on the essence or pith and marrow of such activity lendsA patent is therefore granted to an inventor who
itself well to a legal test for obviousness that satisfies thegoes beyond the level of skill of ‘‘an ordinary mechanic’’.
constitutional requirement for fairness and predictability.The reasoning in Hotchkiss, as in Canadian decisions
Moreover, such a test has sufficient flexibility to bereleased somewhat contemporaneously (Lightning Fast-
employed in a wide range of factual settings and wouldener and Burns & Russell) is clearly pragmatic in nature
not be inherently biased to brand-name or generic phar-and aimed at the essential nature of the inventive activity
maceutical firms. Finally, a purposive construction wouldin each case. It will be recalled that Justice Gibson’s
be in line with English appellate jurisprudence on obvi-decision was applied subsequently in the AZT trial deci-
ousness, and calls for law reform in the United States.sion175 and in other cases employing the more flexible
standard when terms such as ‘‘mechanical’’, ‘‘routine’’,
and ‘‘incremental’’ testing have been employed. As noted Part V: Application to Non-NOC Cases by the United States Supreme Court in John Deere,
Unlike parallel legislation in the United States, liti-Hotchkiss has had enormous implications for American
gation under the NOC Regulations is by way of judicialpatent law.176
review and does not constitute an action for infringe-Regarding the issue of who makes the decision as to
ment. 182 Judicial review under the NOC Regulations iswhether or not an invention is the work of a skillful
considered to be an expedited proceeding and thus sum-mechanic or an inventor, the court was clear that it was
mary in nature. It does not entail a full determination ofto be relevant persons skilled in the art. This determina-
validity or exploration of evidentiary matters that wouldtion is to be made on a case-by-case basis, giving rise to
otherwise be before the court in an infringement pro-the ‘‘functional approach’’ to patentability advocated by
ceeding. 183 Therefore, formal conclusions on patentthe Solicitor General in its amicus curiae brief. In John
validity cannot be determined in litigation under theDeere, it was disputed by several parties that the require-
NOC Regulations, notwithstanding that judicial rea-ment for obviousness under §103 was specifically
soning and pronouncements on the issue of validity mayinserted by amendment to the United States Patent Act
parallel those in actions under sections 55 (infringement)in 1952 to overrule previous considerations of what con-
or 60 (impeachment) of the Act. The object of litigationstitutes ‘‘the flash of inventive genius’’, 177 and thus to
under the NOC Regulations is solely to prohibit thespecifically lower the bar for obviousness. 178 The court
issuance of a NOC under the Food and Drug Regula-rejected this claim however, holding that the language in
tions; 184 if a party desires a formal decision on the issueCuno referring to inventive genius was nothing other
of invalidity, they must avail themselves of remediesthan ‘‘rhetorical embellishment’’ and did not create a
under the Act. 185 Under this reasoning, applied recentlydiffering standard. Rather, the court’s previous decision
in a post-NOC infringement action, 186 the law of obvi-in Cuno stood for the continuing proposition that non-
ousness would not be applicable to cases outside theobvious subject matter is subject matter that extends
NOC Regulations.‘‘beyond the skill of the calling’’. 179 These are the exact
words of Justice Gibson in Burns & Russell. This concept While operation of the NOC Regulations entails
was also picked up on by the Solicitor General in its the odd result of a determination of validity which is
Teleflex brief, as well as by the Law Professors in their only enforced within the ambit of the regulations them-
Teleflex brief. 180 The Law Professors extended this selves, it is clear from the common law and the addition
notion specifically to litigation involving biomedical of section 28.3 to the Act in 1996 that determinations of
technologies. In particular, they claimed that ‘‘method- validity generally are to be made through the lens of
ological advances provided an obvious path to new persons skilled in the art in light of all of the relevant
results that should not themselves be patentable’’, and prior art available as of the claim date. In addition, both
that the Federal Circuit has sufficiently minimized the hurdles over which generic firms must jump (Fox’s
role of persons skilled in the art that it routinely applies injunction against testing per se and the ‘‘no scintilla’’
the obviousness test such that inventions are deemed to cases) in order to obtain a finding of invalidity, and their,
be nonobvious ‘‘even where the prior art demonstrates a application to pharmaceutical cases generally, are outside
clear path for producing the invention’’. 181 the rubric of the NOC Regulations. Indeed, the judiciary
have made no attempt to discriminate between the two
streams of case law in rendering decisions under the
(c) Summary NOC Regulations. Finally, jurisprudence and legal schol-
A purposeful approach to obviousness is advocated arship from the United States and the United Kingdom
for cases under the NOC Regulations. The proposed are outside the scope of the Regulations, yet apply to the
approach focuses not on binary notions of testing/no issue at hand through the identity and inventive capacity
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of persons skilled in the art. Thus, there is no reason why Court of Canada that patent law should lend a degree of
application of arguments made here regarding the role certainty and predictability to potential litigants and pro-
of scientific testing in the lead-up period to an invention vide them with fair notice of when they can reasonably
in the obviousness analysis can not be extended to litiga- expect to infringe the intellectual property rights of
tion beyond the NOC Regulations. others. Moreover, courts have adopted reasoning in the
obviousness analysis that inherently, and thus unfairly,
A note of caution in this regard is the recent biases the legal test in favour of patentees. The result is
infringement opinion of Justice Hughes in Janssen- that generic pharmaceutical firms often lose cases
Ortho v. Novopharm.187 In this case it was held that even improperly on the issue of obviousness, in turn main-
though a prior decision under the NOC Regulations taining dominant market positions for brand-name firms
found Novopharm’s allegation that the impugned claims and monopolistic pricing on products that have often
were invalid on grounds of obviousness was justified, the come off patent on the original new chemical entity. As
same claims were held to be valid and infringed in the such, it was argued the current test creates an improperly
context of subsequent infringement litigation. 188 Justice expanded ‘‘risk zone’’ for both the public and generic
Hughes arrived at his decision based on his finding that firms.
an action under the NOC Regulations does not consti- In addition, setting the threshold for scientifictute res judicata in subsequent infringement litigation. 189 testing to a de minimus level has the effect of placing anIt remains to be seen whether this decision will with- unfair evidentiary burden on generic pharmaceuticalstand appellate scrutiny. companies to prove invalidity within the context of a
regulatory system that the Supreme Court of Canada has
often referred to as ‘‘Draconian’’. 191 This burden is
onerous under conditions where the legal test departsV. Summary and Conclusions 
from the policy objective underpinning the NOC Regu-
lations to balance the interests of brand-name andThe purpose of this article was to analyze Canadian
generic pharmaceutical companies. Indeed, both govern-case law on obviousness pertaining to scientific research
ment policy documents and Supreme Court of Canadaand testing leading up to invention under the NOC
jurisprudence clearly indicate concern for balancing theRegulations, and to highlight confusion in the courts and
interests of both parties under the NOC Regulations.the manner in which the judiciary have attempted to
The same concerns have been expressed in the Unitedgrapple with the issue of testing in the obviousness anal-
States, which, ironically, given its strong innovationysis. Some decisions were found to stand for the proposi-
agenda and pharmaceutical presence has undertaken sig-tion that no experimenting or research whatsoever is
nificant reforms to its linkage regime in order to facilitateallowed, while other cases stand for the opposite proposi-
precisely such a balance. It is submitted that the lack of ation that significant testing does not vitiate the obvi-
clear, consistent, and appropriate test for obviousnessousness attack, while still others purport to use the
represents a departure from maintaining an appropriateformer standard while actually applying the latter. Thus,
balance between the various private and public actorsthere is significant confusion in Canadian case law on
involved in the commercialization, regulation, and con-obviousness under the NOC Regulations.
sumption of pharmaceutical products in Canada.
An analysis of the historical cases cited by Professor Finally, a suggestion was made toward a fair, une-
Fox in his injunction against experimentation, thought, quivocal, and predictable test which has its locus in
or research in the lead-up to invention does not support Canadian law, federal policy underlying the NOC Regu-
the ‘‘no testing’’ approach to obviousness. Indeed, anal- lations, and Supreme Court of Canada jurisprudence in
ysis of this body of case law, along with decisions its leading patent decisions. The proposed ‘‘purposive
released contemporaneously but not cited by Fox, reveal construction’’ of obviousness focuses contextually on
that in fact extensive testing is routinely undertaken by whether or not experimentation or research conducted
persons skilled in the art of pharmaceutical research, and in the lead-up to invention was inventive, rather than
that courts had allowed such testing without vitiating a focusing on binary notions of testing/no testing or
finding of obviousness. This discrepancy was demon- could/would. It provides a test that is fair and flexible for
strated clearly by evidence adduced in an early Sherwin- all parties to litigation, is wholly consistent with appellate
Williams 190 chemical case, as well as in later cases jurisprudence, and which calls for law reform in other
involving pharmaceuticals both outside of and under the jurisdictions with similar patent legislation and policy.
umbrella of the NOC Regulations.
A lack of clear and definitive guidance by the courts
has resulted in considerable arbitrariness, uncertainty,
and a lack of predictability in the case law. It was argued
that this runs afoul of the direction of the Supreme
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VI. Appendix 1 
Table 1. Summary of cases supporting the ‘‘no testing’’ approach to obviousness
Case, Judge NOC Cases Precedent(s) Cited, Notes Non-NOC Cases Precedent(s) Cited, Notes
A. Trace to Fox
Abbott v. Canada† No Testing: Procter & Gamble v. Canada
2006 FC 69 (2004), 32 C.P.R . (4th) 224 at para. 36
Campbell J. (F.C.T.D.); Procter & Gamble Inc. v. Canada
(2004), 37 C.P.R . (4th) 289 at paras. 43–47
(C.A .); AB Hassle v. Genpharm Inc., (2003) F.C. J.
No. 1910 (QL). Claims valid — MOH prohibited
from issuing NOC (clar ithromycin).
Pf izer v. Canada No Testing: Bayer v. Apotex, [1995] O. J. No. 141
2005 FC 1205 (Ont. Gen. Div.) (QL). Claims not obvious.
Heneghan J. Patent invalid on other grounds. (quinapr il)
Pf izer v. Novopharm No Testing: Apotex/Novopharm v. Wellcome,
2005 FC 1299 [1998] F.C. J. No. 382. Claims valid — MOH
Blanchard J. prohibited from issuing NOC (azithromycin)
Sanof i-Synthalebo v. Apotex No Testing: Bayer v. Apotex, [1995] O. J. No. 141
2005 FC 390 (Ont. Gen. Div.) (QL); Cabot Corp. v. 318062
Shore J. Ont. Ltd (1988), 20 C.P.R . (3d) 132; Farbwerke
Hoescht Aktiengesellschaft v. Halocarbon
(Ontario) Ltd. (1979), 42 C.P.R . (2d) 145 (S.C.C.);
Harold Fox, Canadian Law and Practice
Relating to Letters Patent for Inventions, 4th ed.
(Toronto: Carswell, 1969). Claims valid — MOH
prohibited from issuing NOC (clopidogrel)
Procter & Gamble v. Canada No Testing: Smithkline Beecham v. Apotex,
2004 FC 204 2001 FCT 770; Bayer v. Apotex, [1995] O. J.
Snider J. No. 141 (Ont. Gen. Div.); Farbwerke Hoescht
Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
(1979), 42 C.P.R . (2d) 145 (S.C.C.). Claims valid
— MOH prohibited from issuing NOC.
(etidronate)
AB Hassle v. Genpharm No Testing: Pf izer v. Apotex, 2002 FCT 1138;
2003 FC 1443 Bayer v. Apotex, [1995] O. J. No. 141 (Ont. Gen.
Layden-Stevenson J. Div.) (QL); Cabot Corp. v. 318062 Ont. Ltd.
(1988), 20 C.P.R . (3d) 132; Harold Fox,
Canadian Law and Practice Relating to Letters
Patent for Inventions, 4th ed. (Toronto: Carswell,
1969). Claims valid — MOH prohibited from
issuing NOC. (omeprazole)
671905 Alberta v. Q’Max Solutions No Testing: Bayer v. Apotex, [1995] O. J. No. 141
2003 FCA 241 (Ont. Gen. Div.) (QL). Note: FCA said f irst that
Stone J.A . no patent ensues where mechanical testing is
involved, citing Lightning Fastener v. Colonial
Fastener, [1933] S.C.R . 371and FCA decision in
Apotex v. Wellcome, [2000] 10 C.P.R . (4th) 65.
However, tr ial judge was guided by the decision
in Bayer, that expert evidence was adduced at
tr ial that the inventions were not obvious, and
that appeal courts should not inter fere in the
absence of a palpable and over-r iding error,
citing FCA decisions in Apotex v. Wellcome,
(2000) 10 CPR (4th) 65 and Creations v.
Canper Industr ial Products, (1990) 34 CPR (3d)
178. Claims valid and infr inged. Appeal
dismissed. (dr illing machine)
Baker PetroLite v. Canwell No Testing: Bayer v. Apotex, [1995] O. J. No. 141,
2001 FCT 889 60 C.P.R . (3d) 58 (Ont. Gen. Div.); Cabot Corp.
Gibson J. v. 318062 Ont. Ltd [1988], 20 C.P.R . (3d) 132;
Harold Fox, Canadian Law and Practice
Relating to Letters Patent for Inventions, 4th ed.
(Toronto: Carswell, 1969). Claims valid and
infr inged. Appeal dismissed 2002 FC 3 (FCA).
(hydrocarbon sweetening process)
20 Canadian Journal of Law and Technology
Smithkline Beecham v. Apotex No Testing: Bayer v. Apotex, [1995] O. J. No. 141,
2001 FCT 770 60 C.P.R . (3d) 58 (Ont. Gen. Div.); Takach
Gibson J. 1993; Cabot Corp. v. 318062 Ont. Ltd. (1988),
20 C.P.R . (3d) 132; Harold Fox, Canadian Law
and Practice Relating to Letters Patent for
Inventions, 4th ed. (Toronto: Carswell, 1969).
Claims valid. Application dismissed on other
grounds — anticipation. (paroxetine)
Apotex v. Wellcome No Testing: Bayer v. Apotex, [1995] O. J. No. 141
[1998] FCJ No. 382 (QL) (Ont. Gen. Div.) (QL); Takach 1993; Farbwerke
Wetston J. Hoescht Aktiengesellschaft v. Halocarbon
(Ontario) Ltd. (1979), 42 C.P.R . (2d) 145 (S.C.C.);
Harold Fox, Canadian Law and Practice
Relating to Letters Patent for Inventions, 4th ed.
(Toronto: Carswell, 1969). Claims (in part) valid
and infr inged. Action for declaration of
invalidity dismissed. Upheld on appeal [2001] 1
F.C. 495 (F.C.A .), aff ’d (2002) 4 S.C.R . 153.
(A ZT)
Bayer v. Apotex No Testing: Cabot Corp. v. 318062 Ont. Ltd.
[1995] O. J. No. 141 (QL) (1988), 20 C.P.R . (3d) 132; Harold Fox,
Lederman J. Canadian Law and Practice Relating to Letters
Patent for Inventions, 4th ed. (Toronto: Carswell,
1969); Diversif ied Products Corp. v. Tye-Sil
Corp. (1991), 35 C.P.R . (3d) 350 (F.C.A .); Beloit
Canada Ltd. v. Valmet OY (1986), 8 C.P.R . (3d)
289 (F.C.A .); Farbwerke Hoescht
Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
(1979), 42 C.P.R . (2d) 145 (S.C.C.). Breach of
compulsory license. Upheld on appeal: aff irmed
[2002] O. J. No. 193 (O.C.A .), appeal dismissed
[1998[ S.C.C.A . No. 563 (S.C.C.).
Farbwerke v. Halocarbon No Testing: Same 2 cases, along with Major it y
(1979) 42 C.P.R . (2d) 145 (S.C.C.) opinion by Pigeon, also include ‘‘testing and
Pigeon J. development’’ processes, citing: Pope Appliance
Corp. v. Spanish River Pulp and Paper Mills,
[1929] 1 D.L .R . 209; CGE Co. v. Fada Radio,
[1930] 1 D.L .R . 449. Note: Signif icant minor ity
(3 of 7) disagreed, saying invention was more or
less ver if ication
B. Trace to No Scintilla
Pf izer v. Canada No Scintilla: Farbwerke Hoescht
2005 FC 1205 Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
Heneghan J. (1979), 42 C.P.R . (2d) 145 (S.C.C.).
Pf izer v. Canada No Scintilla: Farbwerke Hoescht
2005 FC 1421 Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
Mosley J. (1979), 42 C.P.R . (2d) 145 (S.C.C.)
Aventis v. Apotex No Scintilla: Diversif ied Products Corp. v. Tye-
2005 FC 1504 Sil Corp. (1991), 35 C.P.R . (3d) 350 (F.C.A .).
Tremblay-Lamer J.
Janssen-Ortho v. Novopharm No Scintilla: Farbwerke Hoescht
2004 FC 1631 Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
Mosley J. (1979), 42 C.P.R . (2d) 145 (S.C.C.).
Procter & Gamble v. Canada No Scintilla: Diversif ied Products Corp. v. Tye-
2004 FC 204 Sil Corp. (1991), 35 C.P.R . (3d) 350 (F.C.A .);
Snider J. Farbwerke Hoescht Aktiengesellschaft v.
Halocarbon (Ontario) Ltd. (1979), 42 C.P.R . (2d)
145 (S.C.C.).
AB Hassle v. Genpharm No Scintilla: Farbwerke Hoescht
2003 FC 1443 Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
Layden-Stevenson J. (1979), 42 C.P.R . (2d) 145 (S.C.C.)
Pf izer v. Apotex No Scintilla: Farbwerke Hoescht
(2002) 22 C.P.R . (4th) 466 Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
(F.C.C.) (1979), 42 C.P.R . (2d) 145 (S.C.C.)
Dawson J.
Diversif ied Products v. Tye-Sil No Scintilla: Samuel Parkes v. Cocker Bros.,
(1991) 35 C.P.R . (3d) 350 (F.C.A .) [1929] 46 R .P.C. 241; Canada v. Uhlemann
Decary J. Optical, [1952] 1 S.C.R . 143
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Farbwerke v. Halocarbon† No Scintilla: Pope Appliance Corp. v. Spanish
(1979), 42 C.P.R . (2d) 145 River Pulp and Paper Mills, [1929] 1 D.L .R . 209;
(S.C.C.) Pigeon J. CGE Co. v. Fada Radio, [1930] 1 D.L .R . 449.
Scragg v. Leesona† No Scintilla: Samuel Parkes v. Cocker Bros.,
[1964] Ex. C.R . 649 [1929] 46 R .P.C. 241; Non-Drip Measure v.
Thorson J. Strangers, [1943] 60 R .P.C. 135; Cleveland
Graphite v. Glacier Metal [1950] 67 R .P.C. 149;
Martin and Brio Swan v. Millwood, [1956]
R .P.C. 125
†Deals directly with the issue of testing
Table 2. Summary of cases supporting some degree of testing in the obviousness analysis
Case, Judge NOC Cases Precedent(s) Cited, Notes Non-NOC Cases Precedent(s) Cited, Notes
Janssen-Ortho v. Novopharm† Yes Testing. Factors (pr imary and secondary)
2006 FC 1234 laid out in a new test . Grafts Whirlpool Corp. v.
Hughes J. Camco Inc., [2000] 2 S.C.R . 1067 (diligent in
keeping up) onto Beloit Canada Ltd. v. Valmet
OY (1986), 8 C.P.R . (3d) 289 (F.C.A .). Explicitly
rejects such terms as ‘‘worth a tr y’’ and ‘‘routine
testing’’. The length of time and expenses are
irrelevant. Inventive effort is at the core.
Stipulates that tests are different under NOC
Regs and infr ingement — ‘‘ justif ication’’ has a
different standard. Acknowledges, that court
must weigh all factors and make a decision.
Based on evidence, impugned claim is valid and
infr inged. (levof loxacin)
BMS v. Novopharm† Yes Testing: Pf izer v. Apotex, 2002 FCT 1138;
2005 FC 1458 Janssen-Ortho v. Novopharm, 2004 FC 1631;
Gibson J. Apotex/Novopharm v. Wellcome, [1998] F.C. J.
No. 382. Note: Based on evidence, f inds for
Applicant. Claims valid — MOH prohibited
from issuing NOC. (gatif loxacin)
Aventis Pharma v. Apotex Yes Testing: Janssen-Ortho v. Novopharm, 2004
2005 FC 1504 FC 1631; Apotex/Novopharm v. Wellcome, [1998]
Tremblay-Lamer J. F.C. J. No. 382. Claims invalid — Application
dismissed. (ramipr il)
Pf izer Canada Inc. v. Apotex Inc. Yes Testing: Statement (at 131) favour ing
2005 FC 1421 routine exper imentation as long as it is not
Mosley J. undue testing. Claims invalid — Application
dismissed.  (azithromycin)
Janssen-Ortho v. Novopharm Yes Testing: Pf izer v. Apotex, 2002 FCT 1138;
2004 FC 1631 Apotex/Novopharm v. Wellcome, [1998] F.C. J.
Mosley J. No. 382. Claims invalid — Application
dismissed. (levof loxacin)
Glaxosmithkline v. Canada Yes Testing: Apotex/Novopharm v. Wellcome,
2003 FC 899 [1998] F.C. J. No. 382. Claims invalid —




Pf izer v. Apotex Yes Testing: Apotex/Novopharm v. Wellcome,
(2002) 22 C.P.R . (4th) 466 [1998] F.C. J. No. 382. Note: court also said that
(F.C.C.) a PSA is a paragon of deduction and dexter it y
Dawson J. (Beloit) and also reasonably diligent in keeping
up with advances in the f ield: Whirlpool Corp.
v. Camco [2000] 2 S.C.R . 1067 at para. 74
Claims invalid — Application dismissed.
(sertaline)
Novartis v. Apotex Yes Testing: Apotex/Novopharm v. Wellcome,
2001 FCT 1129 [1998] F.C. J. No. 382, but mainly Genentech
Blais J. Inc.’s Patent, [1989] R .P.C. 147 (C.A .) and an
article by John Bochnovic in 1994. Claims
invalid — Application dismissed. (cyclospor in)
22 Canadian Journal of Law and Technology
Apotex v. Hof fmann-La Roche Yes Testing: Testing was not inventive. It was
(1987) 15 C.P.R . (3d) 217 routine: Beloit Canada Ltd. v. Valmet OY (1986),
Reed J. 8 C.P.R . (3d) 289 (F.C.A .); Windsurf ing
International Inc. v. Tr ilantic Corp., (1985) 8
C.P.R . (3d) 241 (F.C.A .). Application for
declaration patent was invalid allowed.
(sulphonamide tr imethopr im)
Burns & Russell Canada v. Day Yes Testing: Testing is allowable provided it is
(1965) 48 C.P.R . 207 (Ex. Ct.) not ‘‘beyond the expected skill of the calling’’ or
Gibson J. ‘‘beyond the skill of the routineer’’.  Sees as
extension of Cr ipps question. Infr ingement
action dismissed and counterclaim for invalidity
allowed. (masonry-coating)
Canadian Industr ies v. Sherwin- Yes Testing: Mechanical testing by skilled
Williams workshop worker is not inventive. (resinous
(1964) Ex. C.R . 65 condensation products)
Angers J.
Lightning Fastener v. Colonial Yes Testing: Exercise of mechanical skill does
Fastener not equate with exercise of inventive faculty and
[1933] S.C.R . 371 does not deserve a patent monopoly: Durable
Rinfret J. Electr ic Appliance v. Renfrew Electr ic Products,
[1928] S.C.R . 8; Atlantic Works v. Brady, 107
U.S. 192 (2002). Appeal of action for
infr ingement dismissed. (slide fasteners)
Pope Appliance v. Spanish River Pulp Yes Testing: The exercise of mechanical skill,
and Paper including exper imenting , does not amount to a
[1927] Ex. C.R . 29 patentable invention where such exper iments
Maclean P. are not inventive.
†Deals directly with the issue of testing
Table 3. Summary of cases purporting to apply the stringent standard but actually applying the flexible
test for obviousness
Case, Judge NOC Cases Precedent(s) Cited, Notes Non-NOC Cases Precedent(s) Cited, Notes
I. Testing Allowed
Aventis v. Apotex Yes Testing: Janssen-Ortho v. Novopharm, 2004
2005 FC 1504 FC 1631; Apotex/Novopharm v. Wellcome, [1998]
Tremblay-Lamer J. F.C. J. No. 382. No Testing: Sanof i-Synthalebo v.
Apotex, 2005 FC 390; Diversif ied Products
Corp. v. Tye-Sil Corp. (1991), 35 C.P.R . (3d) 350
(F.C.A .). Claims invalid — Application
dismissed. (ramipr il)
Pf izer Canada Inc. v. Apotex Inc. Yes Testing: Statement (at 131) favour ing
2005 FC 1421 routine exper imentation as long as not undue
Mosley J testing. No Testing: Apotex/Novopharm v.
Wellcome, [1998] F.C. J. No. 382; Bayer 1995;
Farbwerke Hoescht Aktiengesellschaft v.
Halocarbon (Ontario) Ltd. (1979), 42 C.P.R . (2d)
145 (S.C.C.); Harold Fox, Canadian Law and
Practice Relating to Letters Patent for
Inventions, 4th ed. (Toronto: Carswell, 1969).
Claims invalid — Application dismissed.
(azithromycin)
Janssen-Ortho v. Novopharm Yes Testing: Pf izer v. Apotex, 2002 FCT 1138;
2004 FC 1631 Apotex/Novopharm v. Wellcome, [1998] F.C. J.
Mosley J. No. 382. No Testing: Bayer v. Apotex, [1995] O. J.
No. 141 (Ont. Gen. Div.) (QL); Farbwerke
Hoescht Aktiengesellschaft v. Halocarbon
(Ontario) Ltd. (1979), 42 C.P.R . (2d) 145 (S.C.C.).
Claims invalid — Application dismissed.
(levof loxacin)
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Glaxosmithkline v. Canada Yes Testing: Apotex/Novopharm v. Wellcome,
2003 FC 899 [1998] F.C. J. No. 382. No Testing: Bayer v.
Noël J. Apotex, [1995] O. J. No. 141 (Ont. Gen. Div.)
GlaxoSmithK line v. Canada (QL); Cabot Corp. v. 318062 Ont. Ltd (1988),
2004 FC 116 (FCC) 20 C.P.R . (3d) 132; Takach 1993; Harold Fox,
Noël J. Canadian Law and Practice Relating to Letters
Patent for Inventions, 4th ed. (Toronto: Carswell,
1969). Claims invalid — Application dismissed.
(carvedilol)
Pf izer v. Apotex Yes Testing: Apotex/Novopharm v. Wellcome,
(2002) 22 C.P.R . (4th) 466 [1998] F.C. J. No. 382. No Testing: Bayer v.
Dawson J. Apotex, [1995] O. J. No. 141 (Ont. Gen. Div.)
(QL); Cabot Corp. v. 318062 Ont. Ltd (1988), 20
C.P.R . (3d) 132; Harold Fox, Canadian Law and
Practice Relating to Letters Patent for
Inventions, 4th ed. (Toronto: Carswell, 1969);
Diversif ied Products Corp. v. Tye-Sil Corp.
(1991), 35 C.P.R . (3d) 350 (F.C.A .); Beloit
Canada Ltd. v. Valmet OY (1986), 8 C.P.R . (3d)
289 (F.C.A .); Farbwerke Hoescht
Aktiengesellschaft v. Halocarbon (Ontario) Ltd.
(1979), 42 C.P.R . (2d) 145 (S.C.C.). Claims
invalid — Application dismissed. (sertraline)
Novartis v. Apotex Yes Testing: Apotex/Novopharm v. Wellcome,
2001 FCT 1129 [1998] F.C. J. No. 382; Genentech Inc.’s Patent,
Blais J. [1989] R .P.C. 147 (C.A .); Bochnovic 1994
article. No Testing: Bayer v. Apotex, [1995] O. J.
No. 141 (Ont. Gen. Div.) (QL); Cabot Corp. v.
318062 Ont. Ltd (1988), 20 C.P.R . (3d) 132;
Beloit Canada Ltd. v. Valmet OY (1986), 8 C.P.R .
(3d) 289 (F.C.A .); Harold Fox, Canadian Law
and Practice Relating to Letters Patent for
Inventions, 4th ed. (Toronto: Carswell, 1969).
Claims invalid — Application dismissed.
(cyclospor in)
I. No Testing Allowed
Smithkline Beecham v. Apotex No Testing: Bayer v. Apotex, [1995] O. J. No. 141
2001 FCT 770 (Ont. Gen. Div.) (QL); Takach 1993; Cabot
Gibson J. Corp. v. 318062 Ont. Ltd (1988), 20 C.P.R . (3d)
132; Harold Fox, Canadian Law and Practice
Relating to Letters Patent for Inventions, 4th ed.
(Toronto: Carswell, 1969). Yes Testing: Can turn
to a logical f irst step, including testing , and still
not have inventive testing. Note: This analysis
was for anticipation. Obviousness failed on
same grounds. Claims valid — Application
dismissed on other grounds (anticipation).
Apotex v. Wellcome No Testing: Bayer v. Apotex, [1995] O. J. No. 141
[1998] F.C. J. No. 382 (Ont. Gen. Div.) (QL); Takach 1993; Farbwerke
Wetston J. Hoescht Aktiengesellschaft v. Halocarbon
(Ontario) Ltd. (1979), 42 C.P.R . (2d) 145 (S.C.C.);
Harold Fox, Canadian Law and Practice
Relating to Letters Patent for Inventions, 4th ed.
(Toronto: Carswell, 1969). Yes Testing: Burns &
Russell v. Day, [1967] 48 C.P.R . 207 (Ex. Ct.);
Genentech Inc.’s Patent, [1989] R .P.C. 147 (C.A .);
Leithiser et al. v. Pengo Hydra-Pull of Canada
Ltd. (1974), 17 C.P.R . (2d) 110 (F.C.A .). Claims
(in part) valid and infr inged. Action for
declaration of invalidity dismissed. Upheld on
appeal [2001] 1 F.C. 495 (F.C.A .); [2002] 4
S.C.R . 153. (A ZT)
Notes:
1 Gunar K. Gaikis, ‘‘Pharmaceutical patents in Canada. An update on 2 S.O.R./93-133.
compulsory licensing ’’ (1992) 42 Patent World 19; Ed Hore, ‘‘A 3 Drug Price Competition and Patent Restoration Act 1984, Pub. L.comparison of US and Canadian laws as they affect generic
No. 98-417, 98 Stat. 1585 (codified as amended at 21 USC §  355 (2000)),pharmaceutical drug entry’’ (1992) 55 Food & Drug L.J. 373; Donald G.
commonly known as Hatch-Waxman. For an analysis of linkageMcFetridge, ‘‘Intellectual property rights and the location of innovative
regulations in the context of patent law generally, see Rebecca Eisenberg.activity: The Canadian experience with compulsory licensing of patented
‘‘The shifting functional balance of patents and drug regulation.’’ (2001)pharmaceuticals’’ (Working Paper for the NBER Summer Institute, 1997
(unpublished)). 20 Health Affairs 119.
24 Canadian Journal of Law and Technology
4 United States Federal Trade Commission, Generic Drug Entry Prior to 25 Bayer, supra note 7 at paras. 61, 66. See also Cabot Corp., supra note 23;
Patent Expiration: An FTC Study (July 2002), online: Federal Trade Fox, supra note 17; Diversified, supra note 19; Beloit, supra note 6;
Commission <http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf>; Farbwerke, supra note 19.
Andrew A. Caffrey & Jonathan M. Rotter, ‘‘Consumer protection, patents 26 Diversified, supra note 19; Farbwerke, supra note 19; Ernest Scragg, supraand procedure: Generic drug market entry and the need to reform Hatch- note 19 and references therein.Waxman’’ (2004) 9 Virg. J.L. & Tech. 1.
27 See e.g., Samuel Parkes, supra note 6 at 248; affirmed by Lord Russell of5 Patent Act, R.S.C. 1985, c. P-4, s. 28.3. See infra note 8 for text. Killowen in Non-Drip Measure Corp. Ltd. v. Strangers Ltd. et. al. (1943),
6 Beloit Canada Ltd. v. Valmet OY (1986), 8 C.P.R. (3d) 289 at 294 (F.C.A.) 60 R.P.C. 135 at 143, Lord Normand in Cleveland Graphite Bronze Corp.
[Beloit]; Crosley Radio Corp. v. Canadian General Electric Co., [1936] et al. v. Glacier Metal Corp. Ltd. (1950), 67 R.P.C. 149 at 156, and by Lord
S.C.R. 551 at 555-556 [Crosley]; Beecham Canada Ltd. et al. v. Procter & Morton of Henryton in Martin and Biro Swan Ld. v. H. Millwood Ltd.
Gamble Co. (1982), 61 C.P.R. (2d) 1 at 27 (F.C.A.) [Beecham]; Samuel (1956),  R.P.C. 125 at 139.
Parkes & Co. Ltd. v. Crocker Bros. Ltd. (1929), 46 R.P.C. 248 at 248. 28 Pope Appliance Corp. v. Spanish River Pulp & Paper Mills, [1929] 1 D.L.R.[Samuel Parkes]; Martinray Industries v. Les Fabricants National Dagendor
209 (P.C.) [Pope Appliance P.C.]; CGE Co.Ltd.  v. Fada Radio, [1930] 1(1991), 41 C.P.R. (3d) 1 at 30 (F.C.T.D.); Canadian Gypsum Co. Ltd. v.
D.L.R. 449 (P.C.); Lightning Fastener v. Colonial Fastener, [1933] S.C.R.Gypsum, Lime & Alabastine Canada Ltd., [1931] Ex. C.R. 180 at 187.
371 [Lightning Fastener]; Ernest Scragg, supra note 19; Burns & Russell v.
7 Supra note 6. See also, Bayer Aktiengesellschaft v. Apotex Inc., [1995] O.J. Day & Campbell, [1967] 48 C.P.R. 207 (Ex. Ct.); Farbwerke, supra note 19.
No. 141, 60 C.P.R. (3d) 58 (Ont. Gen. Div.) (QL) [Bayer cited to QL], aff’d 29 Bayer, supra note 7 at para. 59: ‘‘Thus, Apotex’s position is that the(2002) 16 C.P.R. (4th) 417, (2002) O.J. No. 193 (O.C.A.) (QL), leave to
invention of ’582 was the product of mere workshop analysis, i.e. you tryappeal to S.C.C. refused [1998] S.C.C.A. No. 563 (QL).
one thing and if not successful you try a few other well known tests to
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